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5 . SUMMARY
This thesis is concerned with a study of the clinical and biological effects of 
recombinant human erythropoietin (EPO) which recently became available as a novel 
treatment for the anaemia of end-stage renal disease. The dissertation begins with an 
introductory chapter which contains a historical note and survey of the relevant 
published literature. In this section is included a review of the pathogenesis of renal 
anaemia, the traditional treatment options for this condition, the development of 
recombinant human EPO, the biochemistry and physiology of erythropoietin, the 
metabolic fate of EPO, and the early clinical trials with EPO. This is followed by seven 
chapters of original work undertaken in Cardiff between April 1988 and July 1990:-
Chapter 1 Pharmacokinetics of recombinant human erythropoietin
This chapter reports a study comparing the single-dose pharmacokinetics of 
intravenously-, intraperitoneally-, and subcutaneously-administered EPO in 8 CAPD 
patients, with a view to determining the optimal dosage regimen and route of 
administration for the drug. Following IV administration, serum EPO levels decayed 
mono-exponentially with a mean half-life of 8.2 hours, and only 2.3% of the 
administered dose was lost in the peritoneal dialysis fluid. With IP administration, peak 
serum levels were attained at 12 hours which were only 9% of those obtained following 
IV EPO despite a six-fold larger dose. Using the same dose as that administered IV, SC- 
administered EPO yielded peak levels of only 4% of those obtained after IV EPO, 18 hours 
following the injection. The bioavailability of IP EPO was only 2.9%; that of SC EPO was 
seven times greater at 21.5%. Because of this, and the fact that serum levels remained 
above endogenous levels up to 96 hours, it was concluded that SC administration of EPO 
was likely to be the optimal route for treating dialysis patients. Simulated multiple- 
dose pharmacokinetic analysis suggested that a twice- or thrice-weekly dosage regimen 
would be practicable.
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Chapter 2 Haematological response to recombinant human erythropoietin 
in patients with renal anaemia
This study monitored the haemoglobin concentration, red cell indices, 
reticulocyte count, and iron metabolism in 3 groups of dialysis patients treated with 
EPO:-
Group 1:10 haemodialysis patients treated with IV EPO 240 U/kg/wk.
Group 2: 15 CAPD patients treated with SC EPO 120 U/kg/wk.
Group 3: 13 haemodialysis patients treated with SC EPO 120 U/kg/wk.
In all 3 groups there was an early increase in the reticulocyte count followed by 
a gradual rise in the haemoglobin concentration from around 6 g/dl to a target level of 
10-12 g/dl over a period of about 12-16 weeks. The serum ferritin fell dramatically, 
and 26 of the 38 patients required intravenous iron supplementation to maintain 
adequate iron supplies. A large variation in the maintenance doses required to keep the 
haemoglobin within the target range was observed, but generally lower doses were 
needed when given SC compared to IV administration. Examples were seen of inhibition 
of the response to EPO by infection and malignancy.
Ferrokinetic and blood volume studies were performed in 12 of the CAPD 
patients. A two- to three-fold increase in marrow erythropoietic activity was found 
after EPO therapy, and the rise in red cell mass was associated with a compensatory fall 
in plasma volume such that the circulating whole blood volume remained unchanged.
Chapter 3 Cardiorespiratory benefits following correction of renal  
anaemia by erythropoietin
A number of parameters of cardiorespiratory function were monitored in 10 
haemodialysis patients during the first 12 months of EPO therapy. There were 
considerable improvements in exercise capacity, maximal oxygen consumption, and 
anaerobic threshold (measured by respiratory gas analysis during treadmill exercise
testing) after 2 months’ treatment, and these increases were maintained but not further 
augmented on repeat testing at 4, 8, and 12 months. The carbon monoxide transfer 
factor at rest also showed a dramatic improvement after EPO. In addition there was a 
substantial reduction in exercise-induced myocardial ischaemia following treatment (8 
of 10 patients had significant S-T segment depression on exercise ECG before EPO, 1 of 
10 after 2 months, and 0 of 9 after 12 months of EPO). Left ventricular mass, as 
assessed by echocardiography, progressively decreased over the first 12 months of 
treatment, and 4 of 9 patients showed a significant reduction in cardiac size on chest X- 
ray. Thus, this study showed considerable long-term improvements in 
cardiorespiratory function after EPO therapy.
Chapter 4 Rheological studies during treatment of renal anaemia with 
erythropo ie t in
Whole blood, plasma, and serum viscosities together with red cell deformability 
were measured before and during EPO treatment in order to characterise the possible
role of rheological changes in the pathogenesis of side-effects such as hypertension and
;
arteriovenous fistula thrombosis associated with this drug. Whole blood viscosity 
progressively increased during the first 4 months of treatment, and this increase was 
exponential for a linear increase in haemoglobin concentration. There was no change in 
either plasma or serum viscosity or in red cell deformability during this period. 
Detailed analysis of the relationship between the viscosity changes and the haemoglobin 
concentration indicated that the rheological changes which occur with correction of 
anaemia by EPO can be attributed solely to the increase in circulating red cell mass 
rather than to any changes in the properties of the plasma or the erythrocytes 
themselves.
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Chapter 5 Fistula blood flow and coagulation studies during 
erythropoietin therapy
This study was prompted by the reports of an increased incidence of 
arteriovenous fistula thrombosis in haemodialysis patients treated with EPO. Fistula 
blood flow (measured by Doppler ultrasound) and a variety of tests of coagulation and 
haemostasis were monitored in 10 haemodialysis patients receiving EPO therapy.
Fistula blood flow did not significantly change during the first 12 months of EPO.
Bleeding time improved in all 10 patients after 4 months of treatment, and this 
improvement was maintained at 12 months. There were no significant changes in one- 
stage prothrombin time, kaolin cephalin dotting time, whole blood clotting time, 
prothrombin consumption index, plasma fibrinogen, factor VII, factor VIII, anti­
thrombin III levels, or platelet aggregability to ADP after EPO therapy. In contrast, 
there was a progressive reduction in protein C and protein S levels over the first 4 
months, which reverted to pre-treatment values by 8 and 12 months. Since the levels 
of protein C and protein S attained at 4 months are known to predispose to thrombosis, it 
was interesting to speculate that this effect may contribute to the high incidence of 
fistula thrombosis observed in EPO-treated haemodialysis patients.
Chapter 6 Studies using 125l-labelled recombinant human  
erythropoiet in
In this chapter, the use o f 125iodine-labelled EPO as a tool for examining the 
absorption kinetics and the metabolic fate of EPO is reported. The chloramine-T method 
was used to radio-iodinate carrier-free recombinant EPO. Gel permeation 
chromatography and SDS-polyacrylamide gel electrophoresis were used to characterise 
the nature of the radiolabelled material, and its bioactivity was confirmed by the 
polycythaemic mouse bioassay. The kinetics and clearance of IV-administered ^2^l-EPO 
were studied in 6 normal healthy volunteers, and the reasons for discrepancies with the 
results from pharmacokinetic studies using unlabelled EPO are discussed. Studies in one
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subject failed to identify any smaller molecular weight metabolites of EPO in 
circulation.
In a separate study, the absorption kinetics and bioavailability of 125l-EPO 
injected into 3 different subcutaneous sites in 8 normal healthy volunteers were 
examined. Injection into the thigh resulted in more rapid absorption, higher peak serum 
levels, greater bioavailability, and less drug remaining at the SC site after 96 hours 
compared with injection into the arm or abdomen. These results suggested that the 
optimal site for SC administration of EPO may be the thigh.
Chapter 7 Treating renal anaemia with recombinant human erythro­
poietin: practical guidelines and a clinical algorithm
This chapter contains a series of guidelines which were compiled on the basis of 
the experience gained by the author in treating 42 patients in Cardiff Royal Infirmary 
between 1988 and 1990. In addition to providing an algorithm which focuses 
particularly on the requirements for iron supplementation, the discussion deals with 
such issues as selection of patients for EPO therapy, the optimal starting dose and route 
of administration, the monitoring of iron status during treatment, the desirable rate of 
response and target haemoglobin concentration, and the investigation of an impaired 
response, as well as potential complications. Much of the work contained in this thesis 
has contributed to this set of recommendations, which also reflects the current state of 
knowledge and opinion from the published literature.
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7 . INTRODUCTION
The advent of recombinant human erythropoietin (EPO) represents a major 
breakthrough in the management of patients suffering from the anaemia of end-stage 
renal disease [1,2,3,4]. Prior to its availability a few years ago, many patients with 
renal anaemia either had to endure the disabling symptoms and morbidity associated with 
this condition, or run the risks of side-effects and complications inherent in the only 
available treatment options, namely androgen therapy or blood transfusions. Androgens 
tended to be beneficial only when the anaemia was mild, and were relatively ineffective 
in severe cases [5,6,7]. The side-effects of virilisation and hepatotoxicity also 
precluded their widespread usage [6,7]. Thus, many patients had to rely on regular 
blood transfusions, the effects of which were not only transient, but were associated 
with the risks of transmission of infectious agents (particularly viral), sensitisation to 
histocompatibility antigens, iron overload, transfusion reactions, and possible 
suppression of endogenous erythropoietin production.
It had been recognised for some time, however, that although the pathogenesis of 
renal anaemia was multifactorial, the major factor was a relative deficiency of 
erythropoietin [8]. Thus, patients with renal anaemia generally had circulating levels 
of erythropoietin which were inappropriately low for the degree of anaemia, in 
comparison to those with non-renal causes of anaemia such as iron deficiency [9]. It 
was, therefore, logical to treat renal anaemia with replacement erythropoietin. Until 
recently, however, the technology for synthesising this hormone was lacking, mainly 
due to the problems of isolating material which was present in only picomolar amounts 
in biological fluids. With the advent of recombinant DNA technology, however, this feat 
was finally achieved, thus providing a new therapeutic option in the management of 
anaemia associated with end-stage renal disease.
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8 . LITERATURE SURVEY: RENAL ANAEMIA
This literature survey will review various aspects of renal anaemia including its 
pathogenesis and traditional treatment options, the development of recombinant human 
EPO along with the biochemistry, physiology, and metabolic fate of the hormone, and 
finally the early clinical trials of EPO which occurred prior to the commencement of 
this project. Subsequent publications relevant to this subject will be discussed in each 
of the seven chapters of the thesis as appropriate.
1 . Pathogenesis of renal anaemia
Anaemia is an almost invariable consequence of progressive renal failure 
[8,10,11]. The association was first documented by Richard Bright more than 150 
years ago. The nature of this anaemia was, however, poorly understood until 30 years 
ago when Erslev [12] proved that erythropoietin was the hormone which regulated 
erythropoiesis, and Jacobson et al. [13] demonstrated that EPO originated in the kidney. 
The anaemia previously was thought to be due to the effects of uraemia, since its severity 
was roughly proportional to the degree of renal impairment [14], being particularly 
marked in anephric individuals. The anaemia is hypoproliferative in nature, as 
evidenced by a low reticulocyte count, a reduced ratio of erythroid to granulocytic 
elements in the marrow, and decreased marrow iron turnover as assessed by 
quantitative ferrokinetics [8]. The red cells, although reduced in number, are usually 
normochromic and normocytic unless there are superadded problems such as iron 
deficiency or aluminium intoxication [8,10,11].
A number of factors have been proposed as being contributory to the pathogenesis 
of renal anaemia. These include shortened red cell survival [15,16,17], inhibition of 
erythropoiesis [18,19,20], blood loss [21], iron or folate deficiency [22], 
hyperparathyroidism [23,24], marrow fibrosis, and aluminium excess [25,26], as 
well as a relative deficiency of EPO [8,9]. These will be discussed separately.
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( i ) Shortened red cell survival
Several studies have quantified red cell life-span by means of 51 chromium, 
DF32P, or 14C-cyanate labelling, and have shown this to be reduced in patients with 
chronic renal failure [16,17]. This is generally attributed to chronic low-grade 
haemolysis, which can decrease the life-span of the red cells from around 120 days to as 
little as 40-50 days. Nevertheless, this is not invariable, and many patients with end- 
stage renal disease have a normal red cell life-span.
The cause of the haemolysis is not known. Studies 30 years ago suggested that 
some intravascular substance or substances retained in patients with advanced renal 
failure shortened red cell survival; when red cells from such patients were infused into 
a normal subject, red cell life-span was restored to normal [27]. Neither 
haemodialysis nor peritoneal dialysis significantly improves red cell survival [28,29]. 
In the presence of normal kidneys, however, increased secretion of EPO would easily 
compensate for such a mild degree of haemolysis.
( i i ) Inhibition of erythropoiesis
For more than 30 years, investigators have postulated that inhibitors of bone 
marrow activity play a significant causal role in renal anaemia. Four lines of evidence 
suggested the presence of erythropoietic inhibitors in patients with chronic renal 
failure: (1) In vitro erythropoiesis is impaired when uraemic serum is incubated with 
murine marrow cells in the presence of growth factors, including EPO [20]; (2) plasma 
levels of bioactive EPO in some anaemic haemodialysis patients are elevated [9]; (3) 
infusion of EPO-rich piasma from a patient with aplastic anaemia into several patients 
with advanced renal failure and anaemia failed to elicit a reticulocytosis [30]; and (4) a 
higher proportion of patients treated with continuous ambulatory peritoneal dialysis 
(CAPD) achieve normal haemoglobin levels than do haemodialysis patients [31]. Three 
substances have been incriminated as possible inhibiting solutes: parathyroid hormone 
[24], spermine [32], and ribonuclease [33]. Nevertheless, there are problems with 
accepting the arguments outlined above; these will be considered in turn.
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( 1 )  The in vitro studies, which have shown a reduction in EPO-induced proliferation 
of erythroid progenitor cells after addition of uraemic human serum, lack the 
controls required to support the selectivity and specificity of such inhibitors. 
Thus, the crude extract of the parathyroid gland was inhibitory not only to 
erythroid, but also to granulocyte progenitor cell lines [24]. In addition, 
purified PTH failed to inhibit in vitro erythropoiesis [34]. Spermine, likewise, 
inhibited both erythroid and granulocyte progenitor cell lines [35], and 
furthermore blood levels of spermine are not elevated in dialysis patients [36]. 
Ribonuclease-induced inhibition of erythropoiesis occurred only when 
pharmacological concentrations were added to the culture medium [33]. When 
mouse, rat, or dog erythroid marrow cells were used in culture, both in vitro 
granulopoiesis and megakaryocytopoiesis were inhibited, yet white cell and 
platelet counts in patients with chronic renal failure are usually normal [37].
Of more significance is that when an entirely autologous in vitro culture system 
was used, no inhibition of erythroid progenitor cells with uraemic sera was 
observed [38].
( 2 )  Using bioassay results from concentrated serum, Caro et al. [9] found that some 
uraemic patients had serum EPO levels 3 to 4 times normal. Since these patients 
remained anaemic it was suggested that erythroid inhibitors suppressed the 
marrow response to the modest elevations of EPO. However, concomitant 
quantitation of erythropoiesis was not assessed, and hence an isolated elevated 
serum level is difficult to interpret. Furthermore, for the degree of anaemia 
reported, one would expect EPO levels of around 10 to 100 times normal in 
sub]ects with normal renal function [9]. Subsequent studies have also 
consistently failed to document significantly elevated serum EPO levels in 
uraemic anaemic patients [39].
( 3 )  Although Essers et al. [30] found a reticulocytosis only in patients with mildly 
elevated blood urea and not in those with severe azotaemia after infusion of EPO- 
rich plasma, the number of subjects studied was small, and quantitative 
ferrokinetics were not performed. Eschbach et al. [40] later performed similar 
studies in uraemic anaemic sheep and obtained the same erythroid response to 
EPO-rich plasma in uraemic sheep as in normal sheep. Using this sheep model, 
they found no evidence of either in vivo or in vitro inhibition of erythropoiesis 
by uraemic toxins.
( 4 )  The final observation that has been used to argue for the existence of uraemic 
suppression of erythropoiesis is that the haematocrit of patients starting CAPD 
often rises to normal [31,41]. It has been postulated that this is due to the 
removal of high molecular weight erythropoietic inhibitors which are not 
cleared by haemodialysis. Such mechanisms, however, do not explain why only 
about one-half of patients on CAPD have a significant rise in haematocrit, and 
why, of those that do, most are unable to sustain the rise for more than 18 
months [41].
( i i i ) Blood loss
Significant blood loss occurs in as many as 25% of patients with chronic renal 
failure, thus contributing to their anaemia [21]. The main reason for this is an 
increased bleeding propensity caused by qualitative platelet defects which develop in 
azotaemic patients [42]. This leads to blood loss from the gastrointestinal tract, within 
the skin, and from other sites. In addition, haemodialysis patients can have significant 
losses of blood associated with the dialysis procedure. Platelet dysfunction prolongs the 
bleeding time and impairs platelet aggregation in vitro [43]. Several mechanisms for 
this have been proposed, including decreased platelet factor 3 activity, reduced platelet 
levels of thromboxane A2, an increase in prostacyclin, and suboptimal Factor VIII: von 
Willebrand complex activity.
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( i v )  Iron or folate deficiency
Although not primarily a major cause of renal anaemia, deficiencies of iron or 
folate can certainly exacerbate this condition [22]. Iron deficiency may occur secondary 
to poor dietary intake, e.g. through loss of appetite, or to chronic blood loss as discussed 
above. Folate deficiency may also be dietary in origin, and there is also some folate loss 
through the dialyser. The importance of recognising these factors is that they are 
eminently reversible, and preclude the need for EPO.
( v )  Hyperparathyro id ism /m arrow fibrosis
Hyperparathyroidism, especially osteitis fibrosa, can interfere with 
erythropoiesis, as evidenced by the improvement in renal anaemia in some dialysis 
patients after subtotal parathyroidectomy [23]. As discussed previously, there is 
controversy over whether high PTH levels per se inhibit erythropoiesis, but it was the 
degree of marrow fibrosis, as judged by bone biopsy, and not the elevated PTH levels 
which correlated best as a predictor of erythropoiesis after subtotal parathyroidectomy.
( v i )  Aluminium excess
Aluminium overload, resulting from chronic use of aluminium-containing 
phosphate binders and/or aluminium-containing dialysate produces a non-iron deficient 
microcytic anaemia which can aggravate the anaemia of chronic renal failure [25,26]. 
Treatment of the aluminium excess with weekly injections of desferrioxamine as a 
chelating agent results in an increase in red cell volume within three months, and in 
eventual improvement in the anaemia [11].
( v i i ) Relative EPO deficiency
Patients with non-renal causes of anaemia generally have greatly increased 
serum levels of EPO of the order of 10 to 100 times normal. There is an exponential 
relationship between haematocrit and serum EPO levels in these individuals, such that a 
linear decrement in haematocrit generally results in a disproportionate increase in
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serum EPO. In contrast, patients with renal anaemia have levels of serum EPO which 
are within the normal range of 17-30 mil/ml, i.e. they are inappropriately low for the 
degree of anaemia [8,9]. This is particularly marked in anephric subjects. Thus, 
relative EPO deficiency is unquestionably the major contributory factor in the 
pathogenesis of renal anaemia. Since over 90% of circulating EPO is normally produced 
in the kidney, once renal disease supervenes maximum EPO secretion is presumably 
blunted. This occurs even when EPO production is stimulated by the hypoxia caused by 
anaemia and other forms of impaired oxygen delivery [44]. Thus, the logical approach 
to the treatment of renal anaemia was the use of erythropoietin replacement therapy.
2. Traditional treatments for renal anaemia
Until recently, the only options, other than renal transplantation, for 
ameliorating the anaemia of end-stage renal disease, were androgen therapy and blood 
transfusion. Androgens became popular in the 1970's, and improve renal anaemia 
either by stimulating the erythroid marrow directly or, more likely, by stimulating 
renal or liver EPO production [5,6,7]. Of the commercially available androgens, only 
two became popular, namely nandrolone decanoate and fluoxymesterone. In a 6-month 
crossover study with three other androgens, nandrolone worked the best [7].
Nandrolone decanoate was given weekly, 100-200 mg intramuscularly, for at least 6 
months [5]. If the haemoglobin did not rise significantly, or if the requirement for 
transfusion persisted, a 6-month trial with oral fluoxymesterone, 10-30 mg/day, was 
considered. Unfortunately, virilisation, hepatic dysfunction, and other side-effects have 
limited the use of these agents, which tended to be less effective if the anaemia was 
severe [5,6,7].
Red cell transfusion is clearly the most rapid way of raising the haemoglobin 
concentration, and hence improving anaemic symptoms. However, not only are the 
effects transient, thereby necessitating repeated administration, but transfusions are 
associated with significant risks: (i) transmission of infectious agents such as hepatitis 
B or C, cytomegalovirus, and HIV. Even with proper screening to reduce this risk to a
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minimum, a small number of transfused patients will still be exposed [45]. (ii) 
Sensitisation to histocompatibility antigens. Transfusion-induced anti-HLA antibodies 
are a major reason why some dialysis patients are unable to receive a kidney transplant, 
or have difficulty finding a suitable match, (iii) Suppression of endogenous EPO 
production. Repeated transfusion may suppress marrow activity by switching off what 
little endogenous EPO production there is. This, in turn, sets up a vicious circle 
whereby more frequent blood transfusion becomes necessary [46]. (iv) Iron overload 
is common in dialysis patients who have become transfusion-dependent. This occurs 
because the iron load resulting from the transfusion (200 mg of iron per unit of blood) 
can exceed the body's limited ability to eliminate iron through fixed gastrointestinal 
losses, menstruation, and losses related to surgical procedures. The excess iron is 
initially stored in the reticuloendothelial system, but severe iron overload leads to 
tissue deposition and cellular dysfunction, particularly of the heart, liver, and pancreas 
[47]. (v) Transfusion reactions. While it is rare for these to be life-threatening, mild 
immune reactions are not uncommon. Furthermore, some patients are notoriously 
difficult to cross-match, and finding suitable blood for transfusion is a real problem.
3 . Development of recombinant human EPO
The story of erythropoietin began in the mid-19th century with an astute 
clinical observation by a French physician, Denis Jourdanet, who noted that the blood of 
his surgical patients in the highlands of Mexico was more viscous than normal and 
contained increased numbers of red cells [48]. This was attributed to the low 
atmospheric pressure, and was believed to be advantageous for survival at high altitudes. 
However, the association was felt to be merely fortuitous, and it was not until the end of 
the century that it was demonstrated that red cell production was stimulated in mountain 
climbers exposed to a few weeks of low atmospheric pressure. A humoral stimulator of 
erythropoiesis was first postulated in 1906 by Carnot and Deflandre [49], but proved 
elusive until the 1950's when several key studies were performed. In 1950,
Reissmann showed that exposure of only one of a pair of parabiotic rats to hypoxia was
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sufficient to stimulate erythropoiesis in both [50]. In 1953, Erslev confirmed this 
effect by transferring plasma from anaemic to non-anaemic rabbits [12], and four 
years later Jacobson et al. [13] concluded from studies of anephric rats that this elusive 
factor or hormone, called erythropoietin, was produced by the kidney. This provided a 
logical explanation why patients with chronic renal failure were anaemic.
The quantities of EPO isolated from biological fluids never permitted more than 
brief replacement studies in anephric mammals. Nevertheless, Eschbach and colleagues 
in 1984 demonstrated that the anaemia in uraemic sheep could be completely reversed 
by repeated infusions of EPO-rich plasma obtained from normal sheep rendered anaemic 
by phenylhydrazine and repeated phlebotomy [40]. Obtaining sufficient quantities of 
EPO for clinical trials in humans, however, was impossible until the development of 
genetic bioengineering techniques. The first major breakthrough came in 1977 when 
Miyake et al. [51] first isolated and purified a few micrograms of human erythropoietin 
from 2500 litres of urine obtained from patients with aplastic anaemia. Using 
recombinant DNA technology, oligonucleotide probes coding for portions of the EPO 
molecule were constructed, and used to screen a human genomic library. A fragment 
containing EPO-coding sequences was then isolated and used to screen a cDNA library 
which was constructed from poly-A+ RNA isolated from human foetal liver [52,53]. 
Having isolated and cloned the gene for human EPO, it was then inserted into a suitable 
mammalian vector (Chinese hamster ovary cells). Expression of this gene in this 
system made possible for the first time, the large-scale synthesis of human EPO with an 
identical structure and immunoreactivity to the native hormone [54,55].
4.  Biochemistry and physiology of erythropoietin
Erythropoietin is a glycoprotein hormone which is generated mainly by the 
kidneys [10,13], although up to 10% may be produced in the liver [56,57]. The site of 
synthesis in the kidney remains controversial, with in situ hybridisation localising 
mRNA to peritubular interstitial cells [58,59], or to tubular epithelial cells of the 
renal cortex [60]. In its physiologically active form, EPO is a 165-amino acid
monomeric protein with a molecular weight of 30,400 daltons [55] of which 
approximately 40% is carbohydrate [61]. The carbohydrate residues of EPO are not 
required for its biological activity or target cell specificity when measured in vitro 
[62] but, in common with other plasma glycoproteins, prevent its rapid removal from 
the circulation.
The stimulus for the secretion of EPO is insufficient delivery of oxygen to the 
tissues to meet metabolic demands [63,64]. The EPO, in turn, results in increased 
erythropoietic activity in the bone marrow, and the release of larger numbers of mature 
red blood cells into the circulation. This process is under negative feedback control 
[65]. Thus, hypoxia causes the production of EPO; EPO induces the proliferation of red 
blood cells by the bone marrow; the increased red cell mass improves oxygen transport 
and delivery, thereby alleviating tissue hypoxia and switching off EPO production. 
Hypoxia may be caused by various factors including decreased atmospheric oxygen 
tension (as occurs at high altitude), anaemia, ischaemia, increased metabolic rate, 
respiratory disease, and toxins affecting the oxygen affinity of haemoglobin.
EPO influences erythropoiesis at several stages by stimulating the proliferation 
and differentiation of erythroid precursors, including burst-forming units-erythroid 
(BFU-E), colony-forming units-erythroid (CFU-E), erythroblasts, and reticulocytes 
[66,67]. EPO also stimulates the release of reticulocytes from the bone marrow into 
the bloodstream where they mature into erythrocytes. At a cellular level, 
erythropoietin exerts its action by binding specifically to receptors on the erythroid 
progenitor cells in the bone marrow. Recently, Sawada et al. [68] purified the 
erythroid colony-forming cells from BFU-E generated from peripheral blood, and 
showed specific binding of ^2^l-labelled EPO to these cells by a single receptor (550 
receptors per cell). As these cells matured to erythroblasts, specific binding declined, 
and there were no receptors for EPO on mature red cells. Once bound to its receptor, 
EPO sets in motion a series of events which culminate in the production of the 
erythrocyte. The first measurable processes are an increase in intracellular calcium 
and glucose uptake, followed by a and p globin gene transcription at 6 hours, and an
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increase in transferrin receptor expression. By 12 hours haemoglobin is being 
produced [69].
EPO synthesised by recombinant DNA technology has been found to be identical to 
and indistinguishable from endogenous human urinary EPO, possessing the same 
physicochemical, immunoiogicai, and physiological/pharmacological properties 
[54,55]. It has an activity of greater than 200,000 units/mg protein based on the 2nd 
International Reference preparation [70]. In view of its extreme hydrophobicity, 
current formulations of rHuEPO in solution contain a carrier protein (human serum 
albumin) or a mixture of amino acids to reduce adsorptive losses.
5 . i Metabolic fate of erythropoietin
Remarkably little is known about the distribution, metabolism, and elimination 
in humans of either the endogenous hormone or the recombinant product [71]. The 
volume of distribution of recombinant EPO is equivalent to, or slightly greater than, 
plasma volume. This suggests that EPO is largely distributed intravascularly, with any 
extravascular component being of minor importance. In a number of animal 
investigations, however, a more substantial extravascular distribution space has been 
found [72,73,74,75,76].
5 . i I Metabolism and excretion: the role of the kidney
At present there are major difficulties in assessing the role of the kidney in the 
metabolism of EPO. There is only limited information in humans, and animal 
investigations with homologous hormone have utilised impure preparations and 
relatively insensitive assays. The metabolism of recombinant human EPO in 
experimental animals has been studied using a specific radioimmunoassay but the 
biological relevance of information derived from the use of a xenogeneic hormone is 
uncertain.
In the only human study of rHuEPO pharmacokinetics in individuals with varying 
renal function, Kindler et al. [77] provided evidence against a role for the kidneys in its
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metabolism. Plasma half-lives of 8.5±1.0, 8.8±0.9, and 10.4±2.4 hours were obtained 
from patients with normal renal function (creatinine clearance >80 ml/min), 
moderately impaired renal function (creatinine clearance 10-50 ml/min), and end- 
stage renal failure (creatinine clearance <3 ml/min), respectively. Likewise, there 
was no change in the total body clearance between the 3 groups (0.1197±0.0005, 
0.0855±0.0069, and 0.0803±0.0190 ml/min/kg respectively). Similarly, in two 
groups of normal and uraemic (5/6 nephrectomised) rats, Scigalla et al. [78] found no 
difference in either the plasma disappearance half-lives (12.8 vs 11.5 hours) or the 
renal clearances (0.04 vs 0.05 ml/min/kg) of biologically active ^^S-labelled 
rHuEPO, again suggesting that the kidneys were not primarily involved in the 
metabolism of EPO. Finally, Mladenovic and colleagues [79] reported that the half-life 
of infused homologous EPO-rich plasma in both normal and uraemic sheep was 
approximately 9 hours, and was independent of renal function, the plasma clearances 
being 3.7±2.0 and 3.3±1.8 ml/min, respectively.
In contrast, there are a number of animal studies which do suggest a role for the 
kidney in the metabolism of EPO [72,76,80,81,82]. Spivak and Hogans [82] recently 
found that there was progressive accumulation of iodinated rHuEPO in the kidneys of 
anaesthetised rats compared with other organs, and concluded that the kidney was 
involved to a small extent in the catabolism of the hormone. Furthermore, this was 
supported by their studies with desialated, oxidised EPO, which also appeared to 
accumulate in the kidneys as opposed to other organs. In a pharmacokinetic study in 
healthy and anephric dogs, Fu et al. [76] found a slower clearance of ^ l- la b e lle d  
recombinant human EPO in the anephric animals (half-life = 13.8±1.4 hours; Cl = 
0.008±0.001 l/kg/hour) compared with the intact dogs (half-life = 9.0±0.6 hours; Cl 
= 0.011 ±0.001 l/kg/hour). Emmanouel et al. [72] compared the metabolic clearance 
rates of 125l-labelled purified human EPO in control and acutely nephrectomised rats, 
and found a 32% reduction after nephrectomy (0.19+0.03 vs 0.13±0.01 ml/min/kg). 
This was considerably larger than could be explained solely by cessation of urinary 
excretion of the hormone (7.4%), and thus a role for the kidneys in the degradation of
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EPO was suggested by the authors [72]. Two other groups of workers [80,81] have 
found significantly prolonged plasma disappearance half-lives of endogenous EPO in rats 
after bilateral nephrectomy, compared with controls.
It is well-recognised that a small proportion of EPO is excreted unchanged in the 
urine [51]. This, however, amounts to no more than a few nanograms of protein over a 
24-hour period. Thus, in both animal and human studies, urinary excretion of EPO 
contributes only 3-10% of its overall elimination [72,73,77,83]. Recently, Kindler 
et al. [77] found that the renal clearance of rHuEPO in humans accounted for less than 
3% of total body clearance, and was independent of renal function. Renal clearance rates 
of endogenous EPO ranging from 0.06 to 0.67 ml/min were found in patients with non- 
renal anaemia due to either leukaemia, malignancy, or marrow aplasia [83]. This 
represented a urinary excretion rate of about 10% of the total daily loss. In rats, 
7.4±0.8% of the total body clearance o f 125l-labelled purified human EPO could be 
accounted for by excretion of the labelled hormone in the urine [72]. Urinary clearance 
of 125l-EPO amounted to <0.3% of the glomerular filtration rate, and there was no 
detectable arteriovenous concentration difference of 125l-EPO across the kidney. 
Weintraub et al. [73] found that between 4% and 7% of purified sheep EPO disappearing 
from plasma was recoverable in the urine of unanaesthetised dogs. Thus, it would appear 
that peripheral EPO disposal occurs mainly via non-renal mechanisms. The liver, and 
possibly the erythropoietic tissue of the bone marrow, may be implicated in this 
context.
5 . i i i M e ta b o l i s m :  the  ro le  o f  the  l i v e r
In experimental models, some workers have suggested hepatic degradation of EPO 
[84,85], while other groups were unable to confirm that intact EPO was catabolised in 
the liver [81,86,87,88]. Most of these discrepancies can be attributed to the previous 
lack of standardised assay methods for measuring plasma EPO levels. In isolated 
perfused dog livers, Roh et al. [85] demonstrated rapid hepatic degradation of 
homologous EPO. Both Fischer et al. [86] and Kukral et al. [87], however, found no
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evidence of EPO catabolism in the liver. A more recent study investigating the 
pharmacokinetics of rHuEPO degradation in the isolated perfused rat liver also 
demonstrated no change in either immunoreactive rHuEPO or tracer radioactivity of 
35S-cysteine rHuEPO in the perfusate [88]. Only minute amounts of immunoreactive 
EPO, and on average 0.37% of total tracer added, were retrieved in the bile collected 
[88]. In rats treated with the hepatotoxic agent d-Galactosamine-HCI a small but 
significant prolongation of the plasma disappearance half-life of endogenous EPO was 
found compared with control rats (164 and 105 minutes, respectively) [81]. This, 
however, was minor compared with the effect of bilateral nephrectomy, which increased 
the half-life to 266 minutes. The combination of nephrectomy and d-Galactosamine-HCI 
treatment did not result in a significant further prolongation of the half-life [81]. In 
experiments using isolated perfused rat livers, the same workers found no change in the 
perfusate EPO titre during 4 hours of perfusion, and the results of both these studies led 
the authors to suggest that hepatic degradation of EPO in rats was only minimal compared 
with the action of the kidney.
Thus, as with the studies investigating the role of the kidney in EPO catabolism, 
there is controversy regarding the contribution of the liver to the metabolism of EPO, 
and as yet there is no information in humans.
5 . i v  Metabolism: the role of the carbohydrate moiety of EPO
As discussed earlier, EPO is a heavily glycosylated protein with 40% of its 
molecular size accounted for by carbohydrates [61]. The carbohydrate residues of EPO 
are not required for its biological activity or binding to target cells in vitro [62], but 
they have a crucial role in maintaining the stability of EPO in circulation. If the 
terminal sialic acid groups are removed from the EPO molecule, the resultant 
asialoerythropoietin is rapidly cleared from the circulation by hepatic cells. This, in 
turn, causes apparent loss of biological activity in vivo. Fukuda et al. [89] obtained a 
half-life of about 2 hours for 125l-rHuEPO in rats. In contrast, the desialated EPO was 
cleared from the circulation within 10 minutes. It was suggested that the galactose
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binding protein of hepatic cells is involved in this process [89]. Simultaneous work by 
Spivak and Hogans [82] yielded similar results with 96% of the desialated 125l- 
rHuEPO being cleared from the plasma with a half-life of 2 minutes, in contrast to 180 
minutes for the intact hormone. The bulk of the desialated EPO accumulated in the liver 
where it was rapidly catabolised and its breakdown products released back into the 
plasma. Interestingly, in contrast to the unmodified EPO, there was also early 
accumulation of desialated hormone in the kidneys, marrow, and spleen. Oxidation of 
desialated EPO restored its plasma recovery and clearance to normal, but rendered it 
biologically inactive [82].
6. Early clinical experience with recombinant human erythropoietin
Clinical trials of the recombinant product began in Seattle and London/Oxford in 
1986, and its efficacy in ameliorating the anaemia in patients with end-stage renal 
failure was established at an early stage. Winearls et al. [90] observed an increase in 
the mean haemoglobin concentration from 6.1 to 10.3 g/dl in 10 haemodialysis patients 
over an 11-week period. The need for regular blood transfusion was abolished. Nine of 
the patients reported an improved sense of well-being, while eight noted an increase in 
exercise tolerance. Eschbach and co-workers [91] treated 25 haemodialysis patients 
with doses of EPO ranging from 1.5 to 500 U/kg intravenously thrice weekly. They 
observed a dose-dependent rise in the haematocrit with doses of 15 U/kg or higher. This 
favourable haematological response to EPO was subsequently confirmed by Casati et al.
[92] who reported a mean haemoglobin rise from 6.2 to 10.5 g/dl in 14 patients, and 
Bommer et al. [93] who observed a median haematocrit increase from 19.4% to 30.0% 
or 32.5% depending on the dose used. These studies also documented significant 
improvements in patient well-being, physical performance, appetite, libido, and 
symptoms of Raynaud's phenomenon, as well as a reduction in headaches and fatigue. 
Several patients were able to return to work as a result of treatment with EPO. No 
antibodies against EPO were detected.
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A number of side-effects were noted in these early clinical trials. These included 
'flu'-like symptoms, chills, and transient bone pain, but of greater concern was the 
development of hypertension (occasionally severe, resulting in encephalopathy), and 
thrombosis of the arteriovenous fistula in 7 out of the 62 patients included in the initial 
4 clinical trials [90,91,92,93]. One cerebral thrombotic lesion was also reported 
[92]. All 4 studies noted an increased tendency for clotting in the dialysis lines, 
requiring an average 20% increase in the dose of heparin used during dialysis.
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9 . AIMS OF STUDY
At the time of commencing this work (in April 1988), the efficacy of 
intravenous EPO in ameliorating renal anaemia in haemodialysis patients had been 
established (see previous section). The optimal dosage regimen and route of 
administration, however, had not been ascertained, no studies had been conducted in 
CAPD patients, and little was known about the secondary effects of increasing the 
haematocrit with EPO.
The aim of this project was, firstly, to establish the pharmacokinetics of EPO 
using different routes of administration, with a view to rationalising the most 
appropriate dosage regimen. Secondly, the dose-effect relationship of the drug on the 
haematological response was examined in patients with renal anaemia, comparing 
different doses and routes of administration. Thirdly, the secondary beneficial effects of 
EPO were studied in terms of long-term cardiorespiratory function, as well as recording 
any adverse effects. In relation to the latter, the effects of EPO on various 
haemorheological and coagulation parameters were monitored, along with assessing 
arteriovenous fistula blood flow during treatment. In addition, several studies using 
radiolabelled EPO were carried out to elucidate the absorption kinetics and metabolic fate 
of this hormone. Finally, based on the experience gained during this project, a series of 
practical guidelines and a clinical algorithm for the use of EPO in treating renal anaemia 
were compiled.
CHAPTER 1
PHARMACOKINETICS OF RECOMBINANT HUMAN 
ERYTHROPOIETIN
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INTRODUCTION
In common with insulin and other therapeutic protein hormones, erythropoietin 
is inactivated in the stomach and therefore must be administered parenterally. The 
early clinical trials in haemodialysis patients used intravenously-administered EPO, 
but there was no information at that time as to what was the optimum dosage regimen and 
route of administration for this new drug [94]. Furthermore, the intravenous route 
was clearly impractical for long-term use in patients on continuous ambulatory 
peritoneal dialysis (CAPD) who lacked ready vascular access. A study in rabbits, 
however, had recently shown that 60% of the EPO added to peritoneal dialysis fluid, and 
98% of EPO injected into an empty peritoneal cavity, was absorbed [95]. This suggested 
that intraperitoneal administration of EPO might be a practical therapeutic option for 
CAPD patients.
The purpose of the study described in this chapter was to determine and compare 
the single-dose pharmacokinetics of EPO administered intravenously (IV), 
intraperitoneally (IP), and subcutaneously (SC) to a group of stable CAPD patients.
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PATIENTS AND METHODS 
Patients
Eight patients on regular CAPD were studied. They consisted of 4 males and 4 
females, with a mean age of 62 years (range 43-76 years), and a mean weight of 67 kg 
(range 52-85 kg). The aetiology of their renal disease was varied, and included chronic 
glomerulonephritis, hypertensive nephropathy, diabetic nephropathy, polycystic 
kidneys, and benign nephrosclerosis. Patients had been on CAPD for a range of 7 to 70 
months (median 17 months) and their mean haemoglobin concentration at the start of 
the study was 10.5 g/dl (range 8.6-13.9 g/dl). All were well at the time of the study 
and none had experienced any episodes of peritonitis within the previous 6 months.
Protocol
Patients were admitted to hospital for the study. Baseline serum levels of EPO 
ranged from 18 to 46 mU/ml, with the exception of the patient with polycystic kidneys 
who had a concentration of 236 mU/ml. Each patient received EPO (Boehringer 
Mannheim GmbH, Germany) on 3 occasions separated by at least 4 weeks. The doses 
given were IV 120 U/kg (mean dose per patient = 8043 U), IP 50,000 U, and SC 120 
U/kg. Prior to administration of the drug, three baseline blood samples were taken over 
a 1-hour period for measurement of serum EPO; thereafter samples were withdrawn at 
15 mins, 30 mins, 1, 2, 3, 4, 5, 6, 7, 8, 12, 18, and 24 hours. Additional samples 
were taken at 32, 48, 72, and 96 hours during the subcutaneous phase of the study. 
Serum was separated in a refrigerated centrifuge and stored at -20°C before assay in a 
single batch.
The dialysis regimen was kept constant throughout the initial study period with 3 
bags of solution containing 1.36% glucose administered over the first 24 hours using 8- 
hour, 4-hour, and 12-hour (overnight) dwells sequentially. Dialysate samples were 
taken from each of the 3 bags at the end of their dwell. EPO levels were measured by 
radioimmunoassay using a specific polyclonal antibody [96]. In brief, 100 p.! of serum
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or standard (2nd International Reference preparation of human urinary EPO; 10-500 
mU/ml) and 100 pi of diluted EPO anti-serum were incubated for 24 hours before 
addition of ‘,25l-radiolabelled EPO. Separation of bound versus free ligand was 
accomplished by use of a second antibody technique. The interassay coefficient of 
variation was <8% over a range of EPO concentrations.
Losses of EPO in the dialysate were calculated by measuring the total amount of 
EPO recovered from the peritoneal dialysis effluent during the first 24 hours and 
expressing this as a percentage of the total dose given.
Data analysis
The decline in individual serum EPO concentrations was mono-exponential, and 
results were therefore analysed according to the equation C = Ae'^t (C = serum 
concentration at time t; k = elimination rate constant of a single-compartment open 
model; A = intercept with the ordinate) after baseline levels were deducted. This 
analysis was performed on a microcomputer by standard curve stripping procedures.
Areas under the curves (AUC) were determined by the trapezoidal method with 
extrapolation to infinity. Serum clearance (Cl) was calculated from the dose divided by 
the AUC; distribution volume (Vd) was calculated as described by Ritschei [97].
Bioavailability (f) of IP and SC EPO was assessed using the formula,
AUC ip (or SC) / Dose |p (or SC)
f = ____________________________________
AUC |V / Dose iv
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RESULTS
IV administration of EPO 120 U/kg
Analysis of the serum decay curve indicated that EPO was distributed in a single 
compartment during the first 24 hours with a mono-exponential decay (Fig. 1). Serum 
levels peaked at 3959±758 (SD) mU/ml 15 minutes after administration, and fell to 
5581181 mU/ml at 24 hours. The mean serum elimination half-life of EPO was 8.2 
hours (range 6.2-10.2 hours) with an elimination rate constant (ke|) of 0.087/hr.
The AUC was 3830219375 mU/ml/hr to 24 hours and 45102111405 mU/ml/hr when 
extrapolated to infinity. The mean apparent volume of distribution was 0.033 l/kg 
(range 0.021-0.063) and the mean serum clearance rate was 0.047 ml/min/kg (range 
0.032-0.085) .
Losses of EPO in the peritoneal dialysis fluid ranged from 1.7 to 3.0% (mean 
2.3%) of the total IV dose over the first 24 hours.
IP administration of EPO 50,000 U
Serum EPO levels became detectable within 2 hours of commencement of the 
dwell, reaching a peak of 3751123 mU/ml at 12 hours, and falling slowly to 2871135 
mU/ml at 24 hours with a ke| of 0.032/hr (Fig. 2). The mean AUC to 24 hours was 
643212150 mU/ml/hr giving a bioavailability for IP EPO of only 2.9% (range 1.2- 
6.8%) (Fig. 3).
SC administration of EPO 120 U/kg
There was a significant rise in the serum levels of EPO 2 hours after 
administration, and a peak concentration of 176175 mU/ml was attained at 18 hours 
(Fig. 4). EPO levels then decayed exponentially to 49126 mU/ml at 96 hours with a ke| 
of 0.025/hr. The mean AUC to infinity was 961014862 mU/ml/hr, indicating a 
bioavailability of 21.5% (range 11.3-36.0%) (Fig. 3).
40
Simulated multiple-dose pharmacokinetic profile
Using the method quoted by Ritschel [98], elimination and absorption rate 
constants were calculated for the SC phase of the study. These were estimated as 
0.0163/hr and 0.1684/hr respectively. The constants were then used to predict the 
steady state serum concentrations of EPO at different dosage intervals (Table 1).
DISCUSSION
This was the first comprehensive pharmacokinetic study of EPO in CAPD patients 
to be reported [99]. The half-life of IV EPO in CAPD patients was similar to that 
previously found in haemodialysis subjects [77,100,101] suggesting that peritoneal 
dialysis itself has no significant effect on EPO clearance. The trivial amounts of EPO lost 
in the dialysate, which for practical purposes can be discounted, is further evidence in 
support of this statement. Cumulative results from 15 pharmacokinetic studies of EPO 
involving 141 patients were reviewed recently [71], and the mean plasma elimination 
half-life in this series ranged from 4.0 to 11.2 hours. The subjects studied included a 
mixture of normal healthy volunteers, patients with varying degrees of renal 
impairment not yet requiring dialysis, and haemodialysis and CAPD patients. The 
current evidence suggests that the half-life and clearance of EPO is independent of renal 
function [71,77].
The volume of distribution in this study was of the same order as estimated 
plasma volume and similar to that found in two recent studies in haemodialysis patients 
[100,101], although Kindler et al. [77] in a separate haemodialysis study reported a 
distribution volume of 1.5-2.0 times plasma volume. Animal studies have shown a 
similar variability in distribution volume, from being equal to plasma volume in sheep 
[79] and rats [102], to being 2-3 times plasma volume in dogs [73,76] and rats [74]. 
All the older animal studies, however, used impure preparations and highly variable 
bioassays, which may partly explain these apparent discrepancies.
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A study on EPO absorption from the peritoneal cavity in rabbits [95] 
demonstrated that 60% of EPO in dialysate, and 98% of EPO injected directly into an 
empty peritoneal cavity, was absorbed. This suggested that IP administration of EPO to 
CAPD patients might be a suitable route. The bioavailability data from the present 
study, however, indicate that in order to achieve the same serum profile the IP dose 
needs to be 5- to 10-fold higher than that administered SC. Thus, even though EPO may 
be effective given IP [103], this route of administration results in an unacceptable 
wastage of a costly drug. A number of other studies have subsequently confirmed the low 
bioavailability of IP-administered EPO which was reported as 2.5% (4-hour dwell) and 
3.6% (12-hour dwell) in a study by Boelaert et al. [104], 6.8% in a study by Kampf et 
al. [105], and 8.5% in a study by Gahl et al. [106].
There are two further points of interest arising from the IP serum curve in the 
present study. Dialysis fluid was drained out from the peritoneal cavity after the initial 
8-hour dwell and replaced with a fresh bag containing no EPO. Despite this, serum EPO 
levels continued to rise by a further 50 mU/ml to peak at 12 hours. Also, the 
subsequent elimination of EPO from the serum (ke| = 0.03/hr) occurred much more 
slowly than was evident after IV dosing (ke| = 0.09/hr). Both these findings suggest 
that there was continued absorption of EPO into the bloodstream for several hours after 
the peritoneal cavity was flushed, possibly due to pooling within the lymphatic system.
The bioavailability of EPO given subcutaneously was seven-fold higher than that 
of intraperitoneal EPO, but was still only 22%. Subsequent studies have reported 
estimates of bioavailability after SC administration ranging from 10.2% [104] to 49% 
[105], although most quote values of around 20% [107,108,109]. This is 
considerably lower than that found previously for subcutaneous insulin (50-80%)
[110], heparin (40%) [111], and growth hormone (71%) [112]. There are two 
possible explanations for this. Firstly, EPO may be degraded by peptidases in the skin as 
has been demonstrated for insulin [113], or secondly the larger size of the EPO molecule 
(molecular weight 30,400 daltons) may impede absorption. Emanuele and Fareed
[111] recently showed a striking negative correlation between the size and
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bioavailability of five different molecular weight heparins administered subcutaneously. 
The bioavailability ranged from 3% to 93% depending on the molecular weight of the 
heparin fraction tested.
It has been reported that haemodialysis patients treated with IV EPO will 
maintain their haemoglobin concentration when switched to a lower dose of EPO 
administered subcutaneously [114]. This suggests that the extremely high peaks 
obtained after IV EPO are not required for its therapeutic efficacy. For this reason, and 
since EPO levels after SC administration are maintained for a longer period (3-4 days), 
it would seem reasonable to recommend the subcutaneous route for treating both 
haemodialysis and CAPD patients with EPO.
From the simulated multiple-dose pharmacokinetic data, whilst accepting the 
limitations of extrapolating multiple-dose from single-dose pharmacokinetics, a 
sensible starting dose appeared to be 60-120 U/kg twice weekly, with adjustments in 
the light of the haemoglobin response. This dose was subsequently used for treating two 
groups of anaemic dialysis patients, and the results are presented in the next chapter of 
this thesis. Several other groups of workers have also used SC-administered EPO as the 
basis of their treatment regimens, with encouraging results [115,116,117,118,119]. 
The bioavailability of SC EPO, however, is still less than ideal, a feature likely to be 
related to its molecular size. Assuming, however, that the active moiety of the EPO 
molecule is but a fraction of its entire structure, this raises the possibility of 
synthesising a smaller molecule of similar efficacy but with greater bioavailability. In 
addition, further work is required to investigate the relationship between EPO 
pharmacokinetics and pharmacodynamics, to determine the "ideal" plasma 
concentrations and time profiles of EPO, and to establish the optimal duration of 
interaction of EPO with its receptor to induce the maximum therapeutic effect.
Table 1 Predicted steady state scrum EPO levels at different dosage intervals 
following multiple dosing with subcutaneous EPO 120 U/kg.
DOSAGE INTERVAL (hr)
48 72 96
tmax 11.3 12.9 13.8
Css max 377 281 242
Css min 224 119 70
tmax = time to reach maximum concentration at steady state (hr)
Css max(min) = maximum (minimum) serum concentration at steady state (mU/ml).
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Fig. 1 Serum EPO profile following IV administration of 120 U/kg in 8 stable
CAPD patients.
Results expressed as means ± SD.
SE
RU
M 
EP
O 
(m
U 
/m
l)
500
400
300
200-
100
20 24 28
hours
Fig. 2 Serum EPO profile following IP administration of 50,000 units in 8
stable CAPD patients.
Results expressed as means ± SD.
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Fig. 3 Bioavailability of EPO following IP (50,000 U) and SC (120 U/kg)
administration in 8 stable CAPD patients relative to an IV dose of 
120 U/kg.
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Serum EPO profile following SC administration of 120 U/kg in 8 stable 
CAPD patients.
Results expressed as means ± SD.
CHAPTER 2
HAEMATOLOGICAL RESPONSE TO RECOMBINANT HUMAN 
ERYTHROPOIETIN IN PATIENTS WITH RENAL ANAEMIA
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INTRODUCTION
At the time of starting this project, the efficacy of EPO in being able to correct 
the anaemia of end-stage renal disease in haemodialysis patients had recently been 
established [90,91,92,93]. Such studies had employed EPO given by the intravenous 
route twice or thrice weekly at the end of dialysis. The pharmacokinetic investigation 
detailed in the previous chapter indicated that the subcutaneous route might be 
preferable not only for CAPD patients who lack ready vascular access, but also for 
haemodialysis subjects. The purpose of the study described in this chapter was to 
examine the haematological response to EPO in 3 groups of dialysis patients (2 
haemodialysis, 1 CAPD) using both IV and SC routes of administration and 2 different 
dosage regimens. To this end, the haemoglobin concentration, reticulocyte count, red cell 
indices, white cell and platelet counts, and parameters of iron status were monitored 
regularly over the first few months of EPO therapy. In addition, the effect of EPO on a 
number of ferrokinetic and blood volume measurements were studied in the CAPD patient 
group.
PATIENTS AND METHODS 
Patients
Three groups of dialysis patients were included in this study:- 
Group 1 : 10 haemodialysis patients treated with IV EPO 240 U/kg/wk 
Group 2 : 15 CAPD patients treated with SC EPO 120 U/kg/wk 
Group 3 : 13 haemodialysis patients treated with SC EPO 120 U/kg/wk
Further details of these patients with regard to age, sex, weight, aetiology of 
renal failure, duration on dialysis, and previous transplantation and transfusion history 
are shown in Tables 2, 3, and 4. As might be expected, the CAPD patients, on average, 
were older, and by chance appeared to include relatively more females. The other 
parameters, however, were similar, and the mean starting haemoglobin concentrations 
were likewise fairly comparable among the three different patient groups (6.3±0.6 g/dl 
for Group 1; 6.2±0.8 g/dl for Group 2; and 6.9±0.7 g/dl for Group 3). All patients had
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normal serum ferritin, vitamin B12. and folate levels, and no obvious cause of anaemia 
other than their renal failure.
Group 1 patients were given 120 U/kg of EPO (Boehringer Mannheim GmbH, 
Germany) intravenously twice weekly at the end of dialysis. Patients in groups 2 and 3 
received a subcutaneous injection of EPO (Boehringer Mannheim GmbH), 60 U/kg, into 
the skin of the upper arm (mid-deltoid region) twice weekly. Subsequent dosages were 
titrated according to the initial response: a rise in haemoglobin concentration of less 
than 1 g/dl/month led to a 50%, and occasionally a 100%, increase in the dose of EPO. 
Similar decrements in dosage were instituted if the haemoglobin concentration rose too 
rapidly and when the target haemoglobin level of 10-12 g/dl had been achieved.
All patients received oral iron supplementation in the form of ferrous sulphate 
200-600 mg or ferrous gluconate 300-600 mg per day. Intravenous iron was also 
given as required if there was biochemical evidence of functional iron deficiency 
(transferrin saturation <20%).
Methods
Full blood count indices inciuding haemoglobin concentration, haematocrit, mean 
cell volume (MCV), mean cell haemoglobin concentration (MCHC), and white cell and 
platelet counts were measured weekly on a Technicon (Basingstoke, UK) H1 automated 
blood cell analyser during the first 4 months of EPO therapy, and measured monthly 
thereafter. Reticulocyte counts were estimated from a blood film stained with brilliant 
cresyi blue by counting the number of reticulocytes in 500 red cells. This was carried 
out weekly over the first 4 months of treatment by a single observer. Serum ferritin 
was measured every 2 weeks during the first 4 months of therapy using a sensitive 
immunoradiometric assay [120], and serum iron and total iron binding capacity (TIBC) 
were determined using a standard method [121] at the same time intervals. After 4 
months of EPO, these parameters of iron status were measured monthly. Percentage 
transferrin saturation was expressed as the ratio of serum iron to serum TIBC.
A number of biochemical parameters were also monitored regularly throughout 
EPO treatment; these included standard urea and electrolyte measurements, liver 
function tests (serum albumin, protein, bilirubin, alkaline phosphatase, gamma 
glutamyl transferase, aspartate transaminase, and uric acid levels), and calcium and 
phosphate levels. All of these were measured on automated biochemical analysers.
Twelve of the CAPD patients underwent detailed ferrokinetic and blood volume 
studies prior to EPO, and eight of these had repeat measurements performed after 
achieving their target haemoglobin concentration of >10 g/dl. These studies were 
carried out using the method of Cavill & Ricketts [122] in which the patient's own 
transferrin was labelled with 59Fe. After removal of unbound 59Fe, the labelled 
transferrin was re-injected into the patient. The time course of the clearance of 59Fe 
from the plasma and its reappearance in circulating red cells was monitored over the 
subsequent 10-14 days. This allowed the quantitation of total erythropoiesis (marrow 
iron turnover), effective erythropoiesis (red cell iron turnover), and ineffective 
erythropoiesis, as well as measurement of non-erythroid iron turnover and mean red 
cell life-span. In addition, the circulating red cell volume was determined using 51 Cr- 
labelled autologous red cells, and plasma volume by dilution of the 59Fe-labelled 
transferrin. Whole blood volume was calculated from the sum of these two latter 
parameters [122].
Statistics
Analysis of variance and the two-tailed paired t test were used to assess the 
statistical significance of any changes during EPO therapy. Results are expressed 
throughout as means ± standard deviation.
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RESULTS
( i ) Haemoglobin concentration
This rose in 9 of the Group 1 patients from a mean value of 6.4±0.6 g/dl before 
EPO, to 8.6±1.2 g/dl after 4 weeks, 10.3±1.7 g/dl after 8 weeks, 11.0±0.9 after 12 
weeks, and 11.5±0.7 g/dl after 16 weeks (Fig. 5). There was, however, considerable 
variation between patients in the rate of response to EPO over this period despite 
receiving the same dose of drug (Fig. 6). With further adjustments in the dose of EPO, 
the mean haemoglobin concentration was kept within the target range of 10-12 g/dl for 
up to 12 months of treatment (10.8±0.7 g/dl).
One patient (SW) showed a poor response to EPO over the first few months of 
treatment. Further investigation revealed that she had moderate marrow fibrosis on 
trephine biopsy and intermittent gastrointestinal blood loss from gastric erosions (Fig. 
7). Nevertheless, she eventually attained her target haemoglobin level after nearly 2 
years of therapy and following a switch to daily subcutaneous administration.
Ten of the 15 CAPD patients in Group 2 demonstrated a complete response to EPO 
(attainment of target Hb >10 g/dl) (Fig. 8). Four patients showed a partial response 
(significant rise in haemoglobin concentration but never reaching their target), and one 
patient (MF) exhibited no response at all (Fig. 8). Possible reasons for the incomplete 
response included chronic infection in two patients, and marrow fibrosis (due to 
secondary hyperparathyroidism) in one. The final patient died suddenly at home after 
13 weeks of therapy before she had a chance to reach her target. The "non-responder" 
(MF) was subsequently found to have liver metastases from a breast carcinoma 
diagnosed two years previously, but was believed to be disease-free at the time of 
starting EPO. The mean (±SD) haemoglobin concentration in the ten "responders" was 
6.5±0.9 g/dl before EPO, 7.9±1.4 g/dl at 4 weeks, 8.8±1.4 g/dl at 8 weeks, 10.0±1.5 
g/dl at 12 weeks, 10.1 ±1.7 g/dl at 16 weeks, 11.4±1.3 g/dl at 8 months, and 11.3±1.2 
g/dl at 12 months.
Ten of the 13 haemodialysis patients in Group 3 showed a complete response to 
EPO (haemoglobin 6.8±0.7 g/dl before treatment, 8.4±0.9 g/dl at 4 weeks, 9.6±1.7
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g/dl at 8 weeks, 10.3±1.8 g/dl at 12 weeks, 10.0±1.4 g/dl at 16 weeks, 10.9±1.7 g/dl 
at 8 months, and 11.1±1.3 g/dl at 12 months). The remaining three patients ail 
received renal transplants before reaching their target haemoglobin level.
A comparison of the mean haemoglobin concentrations over the first 12 months of 
treatment revealed very similar results for the 3 groups of "responding" patients (Fig. 
9). This occurred despite the intravenously-treated patients (Group 1) receiving twice 
the starting dose of EPO given to the patients treated subcutaneously (Groups 2 and 3).
Several factors were noted to influence the response to EPO. The commonest of 
these was functional iron deficiency, and many patients required intravenous iron 
supplementation as discussed later. An example of this is shown in Fig. 10. Infection, 
both acute and chronic, also appeared to inhibit the response to EPO, as is illustrated in 
Fig. 11. This shows the dramatic fall in haemoglobin concentration in a 52-year-old 
man who developed a severe chest infection, having been stable at his target haemoglobin 
level for over a year. This did not respond to a doubling in the dose of EPO, and it was 
only after resolution of his infection that his haemoglobin concentration began to climb 
towards its previous value.
( i i ) Maintenance doses of EPO
EPO dosages were adjusted according to the haemoglobin response, the aim being 
to maintain the haemoglobin concentration within the range of 10-12 g/dl. The 
maintenance doses of EPO required to do this after 12 months of treatment varied 
considerably, from 85 to 720 U/kg/wk in Group 1 patients, 60 to 360 U/kg/wk in 
Group 2 patients, and 60 to 240 U/kg/wk in Group 3 patients (Fig. 12). Despite this 
variability, the maintenance doses of the subcutaneously-treated patients (medians 120 
and 123 U/kg/wk) were generally lower than for the intravenously-treated subjects 
(median 188 U/kg/wk).
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( i i i ) Reticulocyte counts
The mean absolute reticulocyte count for the Group 1 patients rose significantly 
after 1 week of EPO treatment from 30±15 x109/l to 110±61 x109/l, and was 
maintained at this level over the first 6 weeks of therapy (123±50 x109/l).
Thereafter, it appeared to settle to lower values which were still significantly above 
baseline (Fig. 13). Similar reticulocyte responses were seen for the other 2 groups of 
patients, and in the CAPD patient group there was a significant difference between the 
results for the "responders" and those for the "poor responders" (Fig. 14).
( i v )  MCV
In all 3 groups there was no significant change in the MCV during the first 4 
months of EPO therapy (Group 1: 91.3±2.4 fl before treatment; 90.8±6.0 fl at 4 weeks; 
92.3±6.4 fl at 8 weeks; 94.8dt5.3 fl at 12 weeks; 93.5±3.3 fl at 16 weeks), (Group 2: 
89.5±5.7 fl before EPO; 89.3±5.4 at 4 weeks; 89.6±5.5 at 8 weeks; 90.0±6.7 fl at 12 
weeks; 90.3±7.6 at 16 weeks), (Group 3: 91.7±8.7 before EPO; 93.5±8.9 at 4 weeks; 
94.6±8.5 fl at 8 weeks; 92.1 ±7.3 fl at 12 weeks; 93.1 ±9.9 fl at 16 weeks). This was 
despite the significant reticulocytosis described previously.
( v ) MCHC
In group 1 patients, no change in MCHC was seen over the first 4 months of EPO 
treatment (32.6±1.9 g/dl before EPO; 33.4±1.0 g/dl at 4 weeks; 34.2±2.0 g/dl at 8 
weeks; 33.2±1.1 g/dl at 12 weeks; 33.4±1.0 g/dl at 16 weeks). In contrast, however, 
significant falls in this parameter were observed in the other two groups of patients 
(Fig. 15). The reason for this apparent discrepancy is not clear. It is likely, however, 
that the fall in MCHC seen in Groups 2 and 3 is caused by the development of mild 
functional iron deficiency.
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( v i )  White cell and platelet counts
No significant changes were observed in either the white cell count or the platelet 
count during EPO therapy in any of the patient groups, values being consistently within 
the normal ranges (data not shown).
( v i i ) Seru  m ferr i t in
Ferritin levels fell dramatically in all groups of patients during the first few 
weeks of EPO (Fig. 16). The median pre-treatment value for Group 1 patients was 126 
pg/I (range 33-1573 jxg/l; normal 15-300 pg/l); this decreased to 85 jxg/l (range 
12-1126 pg/l) after 4 weeks, 54 jxg/I (range 7-1089 jxg/l) after 8 weeks, 56 pg/l 
(range 23-1023 pg/l) after 16 weeks, and 53 jxg/l (range 15-733 pg/l) after 1 year 
of treatment. Five patients, however, required intravenous iron supplementation 
(Imferon; Fisons Pharmaceuticals, Loughborough, UK) at a dose of 2 ml (100 mg 
elemental iron) weekly for 4 weeks at around 6-8 weeks of EPO to maintain an adequate 
iron supply. Similar results were obtained for Group 2 patients [median 130 pg/l 
(range 28-715 jxg/l) before EPO; 65 jig/l (range 22-337 jxg/l) at 16 weeks], and 
Group 3 patients [median 150 jxg/l (range 45-462 pg/l) before EPO; 33 jxg/l (range 
10-152 pg/l) at 16 weeks]. No significant changes in serum B12 or folate were seen 
in any of the groups during EPO therapy.
( v i i i )  Serum iron/T IBC/transferr in  saturat ion
Excluding the 2 patients who were grossly iron-overloaded before starting EPO 
(serum ferritin >1500 jxg/l) and who had pre-treatment transferrin saturations of 
75.3% and 79.6% respectively, the mean transferrin saturation for Group 1 patients 
was 21.6±6.5% before EPO, falling to 14.9±6.5% at 6 weeks (p<0.01). Following IV 
iron supplementation in five patients the transferrin saturation improved to 
26.8±22.9% at 8 weeks and 34.0±26.4% at 16 weeks (Fig. 17). Similar results were 
obtained from the other two patient groups.
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( i x )  Intravenous iron requirements
Despite all patients being prescribed oral iron supplementation, a large number 
required intravenous iron to maintain a transferrin saturation above 20%. This was 
most evident in those who had a starting serum ferritin level below 100 jxg/l (Table 5), 
but many patients who had adequate iron stores (ferritin 100-300 jig/I), and even 3 
patients who had increased iron stores (ferritin 300-1000 jxg/l) before EPO, needed IV 
iron. Neither of the 2 patients who were grossly iron-overloaded prior to EPO required 
intravenous iron supplementation (Table 5).
( x ) Biochemical parameters
There were no significant changes in plasma sodium, potassium, bicarbonate, 
urea, creatinine, or serum calcium, phosphate, total protein, albumin, bilirubin, 
alkaline phosphatase, gamma glutamyl transferase, aspartate transaminase, or uric acid 
levels in any of the patient groups throughout EPO treatment. Three of the 38 treated 
patients (2 haemodialysis, 1 CAPD) had transient individual increases in plasma 
potassium during the acute correction of their anaemia; these settled rapidly with 
further dietary advice.
( x i )  Ferrokinetic studies
in the eight CAPD patients in whom ferrokinetic measurements were performed 
before EPO and after achieving their target haemoglobin concentration, there was an 
increase in the mean (±SD) marrow iron turnover from 78.6±25.1 to 140.1 ±44.5 
pmol/l blood/day; p=0.013 (Fig. 18). Similar rises were observed in the red ceil iron 
turnover (61.8±22.7 to 117.9±43.6 pmol/l blood/day; p=0.012) and the non- 
erythroid iron turnover (25.5±12.6 to 45.5±15.7 pmol/l blood/day; p=0.026). The 
degree of ineffective erythropoiesis decreased from 23.1 ±8.2 to 16.0±6.8% (p=0.05), 
but there was no change in the mean red cell life-span (56.0±22.5 to 47.3±16.7 days; 
p=0.299) (Fig. 18).
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( x i i ) Blood volume studies
The red cell volume in the 8 CAPD patients rose from 594.6±115.1 ml before 
EPO to 1049.0±297.3 ml (p=0.003) after reaching the target haemoglobin 
concentration (Fig. 19). This was associated with a compensatory fall in the mean 
plasma volume from 2991.7±588.5 ml to 2521.3±600.9 ml (p=0.005) such that the 
circulating whole blood volume remained unchanged (3586.3±660.1 ml before EPO to 
3570.3±831.2 ml at target Hb; p=0.91) (Fig. 19). There was a reasonable correlation 
between measurement of haemoglobin concentration and red cell volume both before and 
after EPO treatment (r=0.801) (Fig. 20).
DISCUSSION
The results presented in this chapter confirm the efficacy of recombinant human 
erythropoietin in the treatment of renal anaemia. Thirty of the 38 patients reported 
here achieved the desirable target haemoglobin concentration, and an additional 4 
patients may have reached this had treatment not been discontinued prematurely due to 
renal transplantation in 3 and death in 1. Thus, only 4 patients definitely failed to show 
a complete response to EPO. In two of these, chronic recurrent respiratory infection 
was evident, and in both cases EPO was discontinued after several months. In a further 
patient, moderately severe marrow fibrosis was present on trephine biopsy and the 
highest haemoglobin concentration he achieved during a 2-year treatment period was 
9.0 g/dl (5.5 g/dl pre-EPO). The remaining patient turned out to have metastatic 
carcinoma of the breast which was not known at the time of commencing EPO. She 
therefore had the anaemia of malignancy in addition to renal anaemia, and this did not 
respond to the doses of EPO given.
The two major factors identified in this study which impaired the haematological 
response to EPO were functional iron deficiency and acute or chronic infection. The 
former is defined as a state in which the iron supply to the erythron is inadequate to 
support the needs for erythropoiesis [123,124,125]. This may occur in the presence 
of either deficient or replete body iron stores. The condition is characterised by a low
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transferrin saturation (less than 20%), and on the experience gained in this study and 
elsewhere, is corrected most effectively by administration of intravenous iron 
[123,124,125]. Chronic infection has been reported to suppress the response to EPO 
in other studies. Winearls et al. [90] described two cases in which this was evident, and 
Adamson & Eschbach [126] reported a case of tuberculous osteomyelitis of the hip which 
responded to EPO only after treatment of the infection. Other factors which may 
influence responsiveness to EPO are discussed in Chapter 7 of this thesis.
There was considerable variation among different patients in their initial 
response to the same starting dose of EPO. This was particularly evident in the Group 1 
patients in whom the haemoglobin concentration varied from 6.8 to 13.4 g/dl after 8 
weeks of EPO 240 U/kg/wk (pre-treatment Hb ranging from 5.6 to 7.5 g/dl). 
Consistent with this variability in the sensitivity of response to EPO was the fact that 
the maintenance dosages after 12 months of treatment showed a nine-fold variation from 
85 to 720 U/kg/wk. The reasons for this are almost certainly multifactorial and are 
discussed in greater detail in Chapter 7.
It was of interest to find that the haemoglobin response in the two groups of 
patients treated subcutaneously was very similar to that in the group of patients 
receiving intravenous therapy. This was despite the IV-treated group receiving twice 
the starting dose of EPO. These results suggest that the pharmacodynamics of 
subcutaneous EPO are better than for IV EPO, almost certainly due to the fact that serum 
levels are maintained for a longer period after subcutaneous administration. It also 
suggests that the high pharmacological peak serum levels obtained following IV EPO 
(some 100 times greater than endogenous levels) are not required for its therapeutic 
efficacy. Although, as with IV EPO, the maintenance doses of SC EPO at 1 year show some 
variability, the dosages are generally lower for SC than for IV administration. This has 
obvious cost-saving implications when one is dealing with a drug as expensive as EPO.
The efficacy of subcutaneously-administered EPO has been confirmed in other 
published studies [114,115,116,117,118,119,127,128]. Bommer et al. [114] 
showed that a 50% reduction in dose could be achieved at optimal haemoglobin
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concentration by switching from intravenous to subcutaneous administration. Stevens et 
al. [117] treated 12 CAPD patients with subcutaneous EPO and obtained a brisk response 
to a starting dose of 100 or 150 U/kg thrice weekly. The dose was then reduced to 
12.5-50 U/kg (median 25 U/kg) thrice weekly to maintain a haemoglobin 
concentration between 11.0 and 11.5 g/dl. A similarly rapid response was obtained in 
another study of five transfusion-dependent children on CCPD in whom the haematocrit 
increased from 22% to 33% after only 3 weeks' treatment with EPO given SC at an 
initial dose of 150 U/kg thrice weekly [119]. A much lower SC dose of 50 U/kg twice 
weekly was used by Steinhauer et al. [118] to treat eight adult CAPD patients. In pre­
dialysis patients, similar responses were achieved with 150 U/kg thrice weekly 
intravenously and 100 U/kg thrice weekly subcutaneously [116]. The lowest weekly 
dose of EPO reported to be effective was also given via the subcutaneous route, in a study 
by Granolleras et al. [115]. They found that an adequate haemopoietic response was 
obtained in haemodialysis patients with SC administration of only 14 U/kg daily. Thus, 
the subcutaneous route appears to be gaining popularity not only in CAPD patients 
[117,118,127,128] but also in haemodialysis subjects [114,115,129], and the 
evidence to date suggests that lower doses of EPO may be used when given by this route.
The ferrokinetic studies confirm the expected increase in marrow erythropoietic 
activity after EPO, showing two-fold increases in the turnover of both marrow and red 
cell iron. Thus, the rise in haemoglobin concentration and red cell volume was due to 
increased marrow red cell production since the mean red cell life-span did not change. 
These findings are in contrast to those described in a separate erythrokinetic study by 
Hughes et al. [128] who showed a slight improvement in red cell survival after EPO.
The reason for this discrepancy is not clear at the present time, although in the latter 
study the haemoglobin concentration at the point when the improved red cell survival 
was documented was higher than in the present study. The marginal decrease in 
ineffective erythropoiesis found in the present study is an encouraging finding which 
may also contribute to the rise in red cell mass.
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The increase in red cell volume with a concomitant decrease in plasma volume 
such that the circulating whole blood volume remains the same has also been reported in 
haemodialysis patients by Cotes et al. [130]. In the present study, no specific attempt 
was made to remove extra fluid and thus contribute to the change in plasma volume.
In conclusion, the results of the present study confirm the efficacy of EPO in 
treating the anaemia of end-stage renal disease. Many factors can influence the response 
to therapy which can vary considerably between different patients. On the basis of the 
preliminary data reported here, it would appear that the subcutaneous route may be 
preferable for treating both haemodialysis and CAPD patients, allowing lower 
maintenance dosages and considerable cost savings in the long term.
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Table 5 Requirements for intravenous iron supplementation during EPO therapy 
according to pre-treatment serum ferritin levels.
In i t ia l  f e r r i t in  ( p g / l )  No. of patients No. given IV Fe
<100 17 14
1 00-300  1 1 9
3 0 0 -1 0 0 0  8 3
>1000 2 0
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Haemoglobin response to EPO in 9 haemodialysis patients treated with an 
initial dose of 120 U/kg IV twice weekly.
Results expressed as means ± SD.
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Fig. 6 Variability of haemoglobin response to EPO in 10 haemodialysis patients 
treated with an initial dose of 120 U/kg IV twice weekly.
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Fig. 7 Impaired haemoglobin response to EPO in a 34-year-old female
haemodialysis patient (SW) who was found to have gastrointestinal 
bleeding. Lower panel shows quantitative ^9Fe blood loss studies which 
were strikingly positive. Upper gastrointestinal endoscopy revealed 
several gastric erosions as the presumed source of bleeding.
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Haemoglobin response to EPO in 15 CAPD patients treated with an initial 
dose of 60 U/kg subcutaneously twice weekly.
Results for the 10 responders and 4 poor responders expressed as means 
± SD. Also shown is the lack of haemoglobin response in a 67-year-old 
female (MF) who was subsequently found to have occult carcinomatosis of 
the breast (see text for details).
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Fig. 9 Mean haemoglobin response to EPO in 3 groups of dialysis patients:-
(i) 9 haemodialysis (HD) patients treated intravenously (IV) with 240 
U/kg/wk of EPO; (ii) 10 CAPD patients treated with 120 U/kg/wk of EPO 
given subcutaneously (SC); and (iii) 10 haemodialysis patients treated 
with 120 U/kg/wk of EPO given subcutaneously.
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Fig. 10 Impaired haemoglobin response to EPO in a 26-year-old male 
haemodialysis patient which was restored following intravenous 
administration of 2 ml iron dextran (Imferon; 50 mg elemental iron/ml) 
during week 7.
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Fig. 11 Loss of the haemoglobin response to EPO in a 52-year-old male
haemodialysis patient who developed a severe chest infection after 13 
months of treatment. Doubling the EPO dose had no effect, and it was only 
after the infection had resolved that the haemoglobin response started to 
recover.
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Fig. 12 Maintenance doses of EPO in 3 groups of dialysis patients after 1 year of therapy 
compared to their starting doses.
Upper panel: Group 1. Haemodialysis patients treated with IV EPO at an initial dose of 240 U/kg/wk. 
Middle panel: Group 2. CAPD patients treated with SC EPO at an initial dose of 120 U/kg/wk.
Lower panel: Group 3. Haemodialysis patients treated with SC EPO at an initial dose of 120 U/kg/wk.
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Fig. 13 Reticulocyte response to EPO in 10 haemodialysis patients treated with an 
initial dose of 120 U/kg IV twice weekly.
Results expressed as means ± SD.
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Fig. 14 Mean reticulocyte response to EPO in 15 CAPD patients treated with an 
initial dose of 60 U/kg subcutaneousiy twice weekly. Results are shown 
for the 10 good responders versus the 5 poor or non-responders (see text 
for details).
Abs. reties. = absolute reticulocyte count.
MC
HC
 
(g
/d
l) 
MC
HC
 
(g
/d
l)
35 -i
CAPD pts
34 -
33 -
32 -
31 -
30 -
29
0 4 8 1 2 1 6
35 n
HD pts
34 -
33 -
32 -
31 -
30 -
29
4 1 20 8 1 6
Time (wk)
Fig. 15 Effect of EPO on the mean cell haemoglobin concentration (MCHC) in 
2 groups of dialysis patients treated with an initial dose of 60 U/kg 
subcutaneously twice weekly.
Upper panel = CAPD patients.
Lower panel = Haemodialysis patients.
Results expressed as means ± SD.
*p<0.05, **p<0.01, ***p<0.005 compared with baseline.
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Fig. 16 Effect of EPO on the serum ferritin level in 3 groups of dialysis patients.
Upper panel: Group 1. 10 haemodialysis patients treated with an initial dose of 240 U/kg/wk IV.
Middle panel: Group 2. 15 CAPD patients treated with an initial dose of 120 U/kg/wk SC.
Lower panel: Group 3. 13 haemodialysis patients treated with an initial dose of 120 U/kg/wk SC.
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Fig. 17 Effect of EPO on the transferrin saturation in 10 haemodialysis patients 
treated with an initial dose of 120 U/kg IV twice weekly.
# ------ •  mean ± SD results for 8 of the patients who had no evidence of
excessive iron overload at the start of treatment. Five of the patients 
were given intravenous iron supplementation in the form of iron dextran 
(Imferon) during week 7.
AG, YJ: two patients who had evidence of excessive iron stores at the start 
of EPO therapy (initial serum ferritin >1500 pg/l).
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Fig. 19 Blood volume studies in 8 CAPD patients before and after treatment with 
EPO 120 U/kg/wk SC. The first assessment was carried out immediately 
prior to the onset of therapy; the second study was conducted after a 
haemoglobin concentration of >9 g/dl had been attained. Figures shown 
represent the means ± SD for each parameter (***p<0.005, NS = not 
significant compared to baseline).
RCV = red cell volume; PV = plasma volume; WBV = whole blood volume.
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Fig. 20 Correlation between haemoglobin concentration (Hb) and red ceil volume 
(RCV) in 12 CAPD patients before treatment, and 8 CAPD patients after 
treatment with EPO 120 U/kg/wk SC (r = 0.801).
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CHAPTER 3
CARDIORESPIRATORY BENEFITS FOLLOWING CORRECTION OF 
RENAL ANAEMIA BY ERYTHROPOIETIN
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INTRODUCTION
Patients maintained on chronic haemodialysis have a markedly reduced exercise 
capacity [131,132,133,134] and impaired cardiorespiratory function [135] when 
compared with age- and sex-matched individuals who are non-uraemic. Various factors 
may be contributory including hypertension, hypervolaemia, electrolyte imbalance, 
arteriovenous fistula, calcification, and "uraemic" toxins, but the major determinant 
appears to be chronic anaemia [134].
Longstanding severe anaemia has profound effects on the cardiovascular system, 
resulting in an increase in cardiac output, decrease in peripheral resistance due to 
compensatory vasodilation secondary to tissue hypoxia, and reduced blood viscosity 
[136,137,138,139,140]. In addition, the consequent reduction in oxygen-carrying 
capacity of the blood results in impaired oxygen delivery to the myocardium which, in 
turn, exacerbates myocardial ischaemia in individuals who are already predisposed to 
coronary artery disease as a result of abnormal lipoprotein profiles and other factors 
[141,142,143,144,145]. Furthermore, the anaemia of end-stage renal failure is 
believed to play a major role in the development of left ventricular hypertrophy in 
patients receiving long-term dialysis [146,147]. This, in turn, appears to be an 
important independent determinant of survival in such patients [148].
Previous studies have shown that acute correction of uraemic anaemia by red cell 
transfusion was followed by a normalisation of the changes in cardiac output and total 
peripheral resistance [149]. It was likely, therefore, that long-term correction of 
renal anaemia by recombinant human erythropoietin would have major effects on 
cardiorespiratory function. Furthermore, since cardiovascular complications account 
for more than half of all mortality in patients with chronic renal failure [150], it is 
dearly essential that EPO therapy should not exacerbate these problems. While patients 
receiving EPO have almost universally reported a subjective improvement in well­
being and exercise tolerance [151,152,153], there is limited information on the 
secondary effects of a rise in haematocrit in such individuals, although a recent
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investigation showed a short-term improvement in exercise capacity in haemodialysis 
patients treated with EPO [154].
The study reported in this chapter sought to investigate the long-term effects of 
EPO therapy on cardiac and respiratory function by means of maximal exercise testing 
with concomitant respiratory gas analysis and electrocardiographic monitoring, lung 
function tests, echocardiography, chest radiography, and rheological assessment over a 
12-month period.
PATIENTS AND METHODS 
Patients
Ten patients on regular haemodialysis were studied. These comprised 6 males, 4 
females; the mean age was 43 years (range 22-75 years), and the mean duration on 
haemodialysis was 4.4 years (range 0.6-14.7 years). The cause of their renal disease 
was chronic glomerulonephritis (4 patients), chronic pyelonephritis/interstitial 
nephritis (2 patients), reflux nephropathy (2 patients), hypertensive nephropathy (1 
patient), and congenital renal hypoplasia (1 patient). The mean pre-treatment 
haemoglobin concentration was 6.4±0.63 (SD) g/dl, and all patients had normal serum 
ferritin (>30 }xg/l), vitamin B12 . and folate levels, with no obvious cause for anaemia 
other than their renal failure. Pre-treatment serum EPO levels were all 
inappropriately low for the degree of anaemia, ranging from 25 to 34 mU/ml. Two 
patients had a past history of hypertension although no patients were on anti­
hypertensive medication at the commencement of the study. One patient (34 years, 
female) had suffered 2 previous myocardial infarctions during the preceding 2 years and 
had subsequently undergone a right coronary angioplasty; another patient (75 years, 
male) had a past history of recurrent transient ischaemic attacks, and a further 2 
patients had sustained previous thrombosis of their arteriovenous fistula. No patient 
was known to have any respiratory disease, although three were regular cigarette 
smokers.
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All patients were treated with EPO (Boehringer Mannheim GmbH, Germany) 120 
U/kg given intravenously twice weekly at the end of dialysis. One patient had to be 
withdrawn from the study after 4 months on EPO due to a substantial fall in her 
haemoglobin resulting from persistent gastrointestinal bleeding; results on this patient 
are therefore available up to this point only.
M ethods
The following tests were all performed on the day prior to a dialysis session.
Exercise testing. Symptom-limited maximal exercise testing using the 
Weber treadmill protocol was conducted before, and after 2, 4, 8, and 12 months of 
treatment with EPO. Respiratory gas analysis during exercise was performed by means 
of mass spectrometry (Airspec 2000, Airspec Ltd., Biggin Hill, UK) using the argon 
dilution technique [155]. The duration of exercise and the maximal oxygen consumption 
were recorded, and the anaerobic threshold determined by the method of Matsumura et 
al. [156] using a linear regression technique. Blood pressure was measured every 2 
minutes using a mercury sphygmomanometer. The heart rate and electrocardiogram 
were monitored continuously (Marquette Case System, Marquette Electronics, 
Milwaukee, USA). A standard 12-lead electrocardiogram was recorded after each 
minute. Myocardial ischaemia was defined as the presence of > 0.1 mV horizontal or 
downsloping S-T segment depression. All electrocardiograms were assessed blind by an 
independent observer who was unaware of the clinical details.
Echocardiography. Echocardiograms were performed by the same operator 
using a Hewlett Packard Duplex system (Hewlett Packard, USA) prior to, and after 4, 8, 
and 12 months of treatment with EPO in 9 patients. Care was taken to ensure the same 
transducer positioning for measurement of left ventricular (LV) dimensions from the 
parasternal long-axis view. Left ventricular mass was calculated using the method of 
Devereux & Reichek [157].
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Lung function  tests. Standard lung function tests were carried out before, and 
after 2, 4, and 12 months of EPO therapy in 9 patients. These included measurement of 
peak flow rate (PFR), forced expiratory volume in one second (FEV-j.o). a°d forced 
vital capacity (FVC) obtained from the flow volume curve using the Transfer Test USA 
from PK Morgan Ltd. Functional residua! capacity (FRC), residual volume (RV), slow 
vital capacity (VC), and total lung capacity (TLC) were measured by means of a closed 
circuit helium dilution technique using the same equipment. The transfer factor (TL) 
was measured by the single-breath carbon monoxide method. The results were 
presented in two ways: (i) as observed (TLobs)> and (") corrected to a standard 
haemoglobin concentration of 14.6 g/dl (TLcorr)-
Rheological studies. 20 ml of whole blood was withdrawn into an EDTA- 
coated bottle before EPO therapy was commenced and every subsequent 2 weeks up to 4 
months of treatment, and finally after 12 months of treatment. On each occasion, plasma 
(PV) and serum (SV) viscosities were measured on a Luckham (Burgess Hill, UK) 
viscometer, and whole blood viscosity (WBV) was determined on a Haake (Karlsruhe, 
Germany) CV 100 viscometer at 3 shear rates (3 s"1, 30 s"1, and 300 s_1). Results 
were expressed throughout as mPa sec.
Chest radiology. A standard chest X-ray was performed immediately before 
EPO treatment and after 6 and 12 months of therapy in 8 patients. The cardiothoracic 
ratios were determined on each occasion by the same observer who was unaware of the 
stage of treatment.
Haemoglobin concentration. This was measured weekly on a Technicon 
(Basingstoke, UK) H1 automated blood count analyser up to 4 months of treatment, and 
measured monthly thereafter.
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Analysis of results
Analysis of variance and the paired t test (two-tailed) were used throughout to 
compare results at different time intervals, with the exception of the results of the 
exercise ECG when a Fisher's exact test was employed. Mean values and standard 
deviations quoted are for the group as a whole.
RESULTS
Haemoglobin response
The mean haemoglobin concentration had risen substantially by 2 months of EPO 
therapy (6.4±0.63 g/dl before treatment, to 10.3±1.7 g/dl at 2 months); there were 
further smaller increases to 4 months and the improvement was then maintained but not 
augmented to the end of the study (11.5±0.74 g/dl at 4 months, 11.0±1.2 g/dl at 8 
months, and 10.8±0.68 g/dl at 12 months). Corresponding values for haematocrit were 
0.198±0.02 (0 months), 0.299±0.048 (2 months), 0.343±0.03 (4 months), 
0.335±0.042 (8 months), and 0.326±0.013 (12 months).
Blood viscosity measurements
Plasma and serum viscosities did not change throughout the first 4 months of EPO 
treatment. In contrast, there was a gradual rise in whole blood viscosity measured at all 
three shear rates, the difference being more marked the lower the shear rate 
[3.16±0.62 to 8.08±1.31 mPa sec (3 s“1 shear rate); 2.12±0.29 to 3.83±0.53 mPa 
sec (30 s"1 shear rate); and 1.88±0.29 to 2.84±0.22 mPa sec (300 s_1 shear rate)]. 
These results indicate a 2 .6-, 1.8-, and 1.5-fold rise in WBV over the first 4 months 
for the 3, 30, and 300 s_1 shear rates respectively. There was no further increase in 
the viscosity measurements after 4 and 12 months of EPO therapy.
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E x e rc is e  te s t in g
Exercise duration. The duration of exercise achieved rose in all 10 patients 
after 2 months of treatment (mean 13.2±5.5 to 20.0±6.2 minutes; p<0.0001) (Fig.
21). This improvement was maintained but not further increased on repeat testing at 4 
months (21.8±6.8 minutes) when the mean haemoglobin concentration was higher, 8 
months (21.2±6.7 minutes), and 12 months (20.7±7.5 minutes).
Maximal oxygen consum ption . This rose in 7 of the 10 patients after 2 
months of EPO treatment with a mean increase from 19.1 ±7.0 to 25.0±6.7 m!/min/kg 
(p<0.01). Results obtained at 4 months (25.5±5.1 ml/min/kg), 8 months (24.1 ±7.0 
ml/min/kg), and 12 months (22.8±4.8 ml/min/kg) were unchanged from those 
obtained at 2 months (Fig. 22).
Anaerobic th reshold . Using the method of Matsumura et al. [156], the 
anaerobic threshold could be determined in 9 of the patients before EPO therapy. A 
significant increase in anaerobic threshold was observed after 2 months' treatment with 
EPO with a mean increase from 11.7±3.6 to 15.4±4.8 ml/min/kg (p<0.0005). This 
was maintained over the subsequent 10 months, with the mean response at 4 months 
(14.6±3.3 ml/min/kg), 8 months (14.3±3.1 ml/min/kg), and 12 months (13.9±2.6 
ml/min/kg) being similar to that obtained at 2 months (Fig. 23).
Exercise ECG. Eight out of 10 patients had one or more areas of significant S-T 
segment depression prior to EPO therapy (Table 6); only one of these was known to have 
coronary artery disease and experienced anginal symptoms. The abnormalities resolved 
in all but one patient (BB) after 2 months of treatment (p=0.019; Fisher's exact test) 
despite a significant increase in the duration of exercise performed (an example is 
shown in Fig. 24). After 4 months of treatment this patient (BB) too had complete 
resolution of her S-T segment depression. Another patient (HL), however, had some 
recurrence of ischaemia at 4 months, though to a lesser extent than during his pre­
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treatment assessment. This S-T segment depression occurred only after 20.7 minutes of 
exercise which represented considerably more physical effort than was achieved prior 
to EPO therapy (11.9 minutes). At 8 months, only one of the 9 patients who had an 
exercise ECG performed showed any evidence of myocardial ischaemia, and at 12 months 
all 9 patients were free of ECG evidence of ischaemia. No significant cardiac 
arrhythmias were noted during exercise at any stage of testing, and there were no new 
ischaemic ECG changes or symptoms in the two patients who were free of these before 
EPO therapy was commenced.
Echocardiography
There was a significant progressive reduction in LV mass from 354±169 g 
before EPO to 311 ±149 g after 4 months' treatment, 291 ±112 g after 8 months', and 
251±95 g after 12 months' therapy (p<0.01) (Fig. 25). This was more obvious the 
greater the degree of left ventricular hypertrophy at baseline (see example in Fig. 26). 
Left ventricular internal dimensions in systole and diastole were not significantly 
altered by EPO therapy, though there was a downward trend (3.9±1.0 versus 3.6±1.2 
cm, and 5.3±1.1 versus 4.9±1.2 cm at 0 and 12 months respectively) (Fig. 27).
Chest radiology
Four of 8 patients showed a significant (>10%) reduction in cardiothoracic ratio 
(CTR) after 6 months of EPO (Fig. 28). The mean CTR decreased from 0.51 ±0.04 to 
0.46±0.04 over this period (p<0.05), and this improvement was maintained on repeat 
examination at 12 months (0.46±0.04). No other changes in the chest X-ray were 
noted.
Lung function tests
There was a significant increase in CO transfer (TLobs) *n all patients after 2 
months of EPO (mean 15.5±2.9 to 18.6±3.7 ml/min/mmHg; p<0.005) (Fig. 29). A 
further increase to 21.8±3.3 ml/min/mmHg (p<0.001) was observed at 4 months,
64
which was maintained on re-testing at 12 months (21.4±4.5 ml/min/mmHg).
However, there was no significant change when values were corrected to a standard 
haemoglobin concentration (TLcorr)- There were likewise no significant changes in the 
other parameters of lung function (PFR, FEV-|.o» FVC, FRC, RV, VC, or TLC) over the 12 
months of treatment.
Blood pressure
All patients were normotensive at the start of EPO therapy (mean MAP =
102±19 mmHg) and none were receiving anti-hypertensive medication. After 4, 8 , and 
12 months of EPO the mean MAP was unchanged (108±20, 110±25, and 107±17 
mmHg, respectively); however 2 patients required hypotensive therapy. Patient RP 
commenced atenolol at week 7; this was subsequently discontinued at week 12 and he 
remained normotensive thereafter. Patient EE required triple anti-hypertensive 
therapy to control her blood pressure and she remained on atenolol and prazosin at 12 
months.
DISCUSSION
The data presented here provided, for the first time, information on the long­
term effects of EPO on cardiac and respiratory function [158]. In particular, this study 
has demonstrated beneficial responses to the recombinant hormone in terms of exercise 
capacity, exercise-induced myocardial ischaemia, left ventricular mass, cardiac size as 
assessed by chest X-ray, and lung function tests, which were maintained over at least 12 
months once a stable haemoglobin concentration was reached.
Numerous clinical trials have demonstrated an almost universal haemopoietic 
response to EPO therapy in dialysis patients (1,2,3,4,90,91,92,93,159]. Many of 
these studies document an increase in patient well-being, quality of life, and subjective 
improvement in physical capacity [151,152,153]. There is, however, a relative 
paucity of published information on the effect of EPO on cardiac or respiratory function. 
Although an improved peripheral oxygen delivery resulting from partial correction of
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renal anaemia with EPO would be expected to be beneficial, other related changes might 
be less so. Associated with the rise in haematocrit is an exponential increase in whole 
blood viscosity (see Chapter 4) which, in turn, results in an increased peripheral 
resistance [160], and which could adversely affect coronary blood flow. Peripheral 
resistance is known to increase after EPO therapy [161,162,163,164]. Furthermore, 
studies in hypertensive patients have suggested that there is a strong relationship 
between whole blood viscosity and the development of left ventricular hypertrophy 
which is independent of blood pressure levels [165]. Other implications of an increased 
blood viscosity have been summarised in a recent review article [160].
This study was therefore aimed at examining the effects of partial correction of 
renal anaemia on cardiac and respiratory function in haemodialysis patients utilising, in 
particular, maximal exercise testing with respiratory gas analysis which has been 
shown to be one of the best methods available for testing cardiorespiratory function 
[166,167]. Haemodialysis patients are known to have impaired exercise capacity 
[131,132,133,134], largely due to anaemia [134]. The work reported in this chapter 
has confirmed Mayer and colleagues' results showing an early improvement in exercise 
tolerance, maximal oxygen consumption, and anaerobic threshold after EPO treatment 
[154]. In addition, the results presented here show that these benefits are maintained 
in the longer term. This is almost certainly due to the better oxygen-carrying capacity 
of the blood which would also explain the substantial improvements in CO transfer 
(TLobs) found in the present study. Cotes et al. [168] previously showed that treatment 
of iron deficiency anaemia resulted in a rise in CO transfer; the present study provides 
confirmatory evidence that this also occurs with EPO therapy.
Of even greater interest is the reversal of exercise-induced myocardial 
ischaemia after EPO therapy in all 8 patients who had evidence of S-T depression on 
exercise ECG prior to treatment. This suggests that the improved oxygen delivery to the 
myocardium is outweighing the possible deleterious effect of the increased blood 
viscosity on coronary blood flow. Furthermore, this amelioration of cardiac ischaemia 
was achieved despite a considerable increase in workload (a doubling of the exercise time
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results in a disproportionately greater increase in work output). Two of the 8 patients 
with cardiac ischaemia had symptomatic angina prior to EPO; both noted a subjective 
improvement in their symptoms with less frequent utilisation of their sublingual 
glyceryl trinitrate spray. In the context of current concern about the development of 
thrombotic complications including myocardial infarction, these results suggest that the 
benefits outweigh the risks, and that ischaemic heart disease should not be regarded as a 
contraindication to EPO therapy. Care should still be taken, however, not to raise the 
haematocrit to too high a level in case the benefit is lost.
Longer term beneficial cardiac effects may also result from EPO therapy.
Patients with moderately severe anaemia have a high cardiac output in an attempt to 
compensate for their reduced oxygen carrying capacity. This results In compensatory 
hypertrophy of the left ventricle [146,147], a finding which is common in 
haemodialysis patients and which has recently been shown to be an important 
independent determinant of survival in such patients [148]. There is good reason to 
speculate that if the anaemia is corrected with EPO and blood pressure control 
maintained, progression of left ventricular hypertrophy may be retarded or even 
partially reversed. A recent study has reported a reduction in LV mass following renal 
transplantation [169], attributing the effect to an increased haematocrit and closure of 
arteriovenous fistulae. The decline in estimated LV mass of approximately 30% found in 
the patients in the present study after 12 months of EPO therapy shows that such an 
improvement can be achieved solely by correction of the anaemia. The decrease in 
cardiothoracic ratio seen on chest radiology is also likely to have been due to the 
decreased LV mass, plus or minus a reduction in ventricular volumes. Whilst London et 
al. [170] found a decrease in left ventricular end-diastolic diameter, the results of the 
present study, though showing a downward trend, failed to reach statistical significance. 
Unlike the other measurements in this study where no improvement occurred after the 
first few months of treatment, LV mass showed a progressive decline with time over the 
12 months of observation, emphasising the benefits of maintaining a higher haematocrit 
for an extended period. This confirms and extends single end-point studies in this [171]
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and another group [170] of haemodialysis patients, both of which showed a similar 
reduction in LV mass index. Whether this change will be associated with improved 
survival of dialysis patients will require long-term studies, but there is circumstantial 
evidence to suggest that this might be the case [148]. A number of other 
echocardiographic parameters have also been shown to improve after EPO therapy 
[172], although in the same study no changes were found in the thickness of the 
interventricular septum or the left ventricular posterior wall, possibly due to the 
rather short follow-up.
In conclusion, EPO treatment of uraemic anaemia is associated with 
improvements in cardiac function as judged by exercise capacity and oxygen consumption 
as well as a decrease in myocardial ischaemia and left ventricular mass. These benefits 
are maintained over at least 12 months of therapy.
Table 6 Exercise ECG S-T segment changes recorded in 10 haemodialysis patients 
before, and after 2, 4, 8 , and 12 months of EPO therapy
In itia ls Site Pre-EPO 2 mths 4 mths 8 mths 12 mths
SW L
I
2.0 -
HL L 1.0
I 1.2 - 1.2 - -
BB L 1.0 1.4
I 1.2 1.4 - - -
RP L 2.0 _ _ _ _
I - - - - -
EE L 1.0 _ _ _ _
I - - - - -
SR L _ _ _ _ _
I - - - - -
AF L 1.0
I 1.0 - - - -
CL L 2.2
I 1.2 - - - -
/G L 3.0
I 1.0 - - - -
YJ L _ _ _ _
I - - - - -
Results shown are the shifts in S-T segments of >1 mm (0.1 mV) in leads V5 (lateral 
(L) aspect of heart) and aVf (inferior (I) aspect of heart). There were no significant 
changes in lead V-j (anterior aspect of heart) in any of the patients during exercise.
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Fig. 21 Effect of EPO treatment on exercise duration during treadmill testing in 
10 haemodialysis patients.
Data also given as mean ± SD for the group as a whole.
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Fig. 23 Effect of EPO treatment on anaerobic threshold during treadmill testing in 
9 haemodialysis patients.
Data also given as mean ± SD for the group as a whole.
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Effect of EPO treatment on left ventricular (LV) mass in 9 haemodialysis 
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**p< 0 .0 1 .
Fig. 26
12 months
Echocardiographic recording before and after 12 months of EPO therapy 
in a 26-year-old male haemodialysis patient.
Note reduction in thickness of inter-ventricular septum (arrows).
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Fig. 27 Effect of EPO treatment on left ventricular internal dimensions in 
systole (LVIDs; upper panel) and diastole (LVIDd; lower panel) in 
9 haemodialysis patients.
Data also given as means ± SD for the group as a whole, 
ns = not significant.
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Fig. 28 Effect of EPO treatment on cardio-thoracic ratio (CTR) on a chest X-ray 
in 8 haemodialysis patients.
Data also given as mean ± SD for the group as a whole.
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CHAPTER 4
RHEOLOGICAL STUDIES DURING TREATMENT OF RENAL 
ANAEMIA WITH ERYTHROPOIETIN
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INTRODUCTION
The previous two chapters have reported beneficial haematoiogical and 
cardiorespiratory effects in anaemic dialysis patients treated with EPO. Many other 
studies have confirmed the efficacy of this new agent in the treatment of renal anaemia 
[1,2,3,4,126], and the patients themselves report dramatic improvements in well­
being, physical capacity, and energy reserve [90,91,92,93]. Two major side-effects of 
this therapy, however, have emerged, namely hypertension (occasionally severe, 
resulting in encephalopathy) [1,2,3,4,90,91,92,93,173] and thrombosis of the 
arteriovenous fistula [90,92,93,174,175]. It has been suggested that the increase in 
blood viscosity associated with the rise in haematocrit plays a major role in the 
pathogenesis of these complications [160,173,176].
The purpose of the studies reported in this and the next chapter was to investigate 
potential aetiological factors in the development of hypertension and thrombotic events 
associated with EPO therapy. In this chapter is contained a detailed analysis of the 
rheological changes which occur following EPO treatment, and in Chapter 5 a study on 
the effect of EPO on a number of coagulation and haemostatic parameters is reported.
In addition to an increased quantity of circulating red cells [177,178], many 
other factors can potentially influence changes in whole blood viscosity. These include 
alterations in shear stresses secondary to changes in vascular dynamics, and changes in 
red cell aggregation and deformability [178] (which in turn are affected by the mean 
red cell volume (MCV), the mean red cell haemoglobin concentration (MCHC) [179], the 
presence of red cell inclusions, and alterations in the shape of the red cells [180]). 
Changes in plasma constituents such as fibrinogen [178], and in the characteristics of 
the white cells and platelets, will also have an effect. Patients with chronic renal 
failure not infrequently have abnormalities in one or more of these parameters, and the 
effect of EPO in this context has not been fully evaluated.
The present study outlines a number of rheological investigations in 30 dialysis 
patients treated with EPO with a view to characterising the associated changes in blood 
viscosity. Whole blood, plasma, and serum viscosities, and plasma fibrinogen levels,
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were measured in 10 haemodialysis patients during EPO therapy. Red ceil 
deformability, MCV, MCHC, and reticulocyte count were monitored in a further two 
groups of dialysis patients (10 haemodialysis, 10 CAPD) receiving EPO.
PATIENTS AND METHODS 
P a tie n ts
Thirty patients were studied. All were severely anaemic (haemoglobin <8.0 
g/dl) with normal serum ferritin, vitamin B-J2 . and folate levels, and no obvious cause
for anaemia other than their renal failure. They were divided into three groups:-
Group 1: 10 haemodialysis patients treated initially with 240 U/kg/week of 
EPO (Boehringer Mannheim GmbH, Germany) given intravenously in 2 separate doses at 
the end of dialysis. These comprised 6 males and 4 females; mean age 43±16 (SD) 
years; mean duration on haemodialysis 4.4 years (range 0.6-14.7 years). Three of the 
patients were transfusion-dependent prior to receiving EPO. The cause of their renal 
disease was chronic glomerulonephritis (4 patients), chronic 
pyelonephritis/interstitial nephritis (2 patients), reflux nephropathy (2 patients), 
hypertensive nephropathy (1 patient), and congenital renal hypoplasia (1 patient). 
Their mean pre-treatment haemoglobin concentration was 6.4±0.6 g/dl.
Group 2: 10 CAPD patients treated initially with 120 U/kg/week of EPO 
administered subcutaneously in 2 separate doses. These consisted of 3 males and 7 
females; mean age 54±18 years; mean duration on CAPD 4.1 years (range 1.7-8.2 
years). None of the patients was transfusion-dependent prior to receiving EPO. The 
cause of their renal disease was chronic glomerulonephritis (2 patients), chronic 
pyelonephritis/interstitial nephritis (2 patients), hypertensive nephropathy (1 
patient), obstructive uropathy (1 patient), post-partum renal failure (1 patient), and 
chronic renal failure of unknown aetiology (3 patients). The mean pre-treatment 
haemoglobin concentration for this group was 6.1 ±0.9 g/dl.
Group 3: 10 haemodialysis patients treated initially with 120 U/kg/week of 
EPO administered subcutaneousiy in 2 separate doses. These comprised 5 males and 5 
females; mean age 37±19 years; mean duration on haemodialysis 2.7 years (range 0.3- 
6.6 years). Two of the patients were transfusion-dependent prior to receiving EPO. The 
cause of their renal disease was IgA nephropathy (1 patient), chronic 
pyelonephritis/interstitial nephritis (1 patient), reflux nephropathy (3 patients), 
obstructive uropathy (2 patients), polycystic kidneys (1 patient), and chronic renal 
failure of undetermined cause (2 patients). Their mean pre-treatment haemoglobin 
concentration was 6.8±0.7 g/dl.
In addition, 2 groups of normal, healthy volunteers drawn from the hospital staff 
were recruited to provide control data. The first of these (Group A) comprised 27 
subjects (13 males, 14 females; mean age 32±7 years; mean haemoglobin concentration 
14.6±1.3 g/dl) in whom whole blood and plasma viscosity was assessed. The second 
group (Group B) consisted of 30 subjects (15 males, 15 females; mean age 34±7 years; 
mean haemoglobin concentration 14.5±1.3 g/dl) in whom red cell deformability was 
measured.
M ethods
All blood samples for rheological studies were taken with minimal stasis from an 
antecubital vein into bottles coated with EDTA K2 (1.5 mg per ml blood), and tested 
within 3 hours.
Full blood count indices including haemoglobin concentration, haematocrit, 
MCV, and MCHC were measured weekly on a Technicon (Basingstoke, UK) H1 automated 
blood cell analyser up to 4 months of treatment, and measured monthly thereafter. The 
reticulocyte count was estimated by a single observer from a blood film stained with 
brilliant cresyl blue by counting the number of reticulocytes in 500 red cells.
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Whole blood v iscos ity  was measured at 37°C in the Group A control subjects 
on one occasion, and in the 10 Group 1 patients before EPO was commenced and every 
subsequent two weeks up to 4 months of treatment, and again after 12 months of 
treatment. This was performed using a Haake (Karlsruhe, Germany) CV 100 rotational 
viscometer. Measurements were made at shear rates of 3, 30, and 300 s"1 on whole 
blood, semi-packed cells, and packed cells (the latter two preparations made by 
decanting increasing amounts of plasma after centrifugation at 2,000 g for 10 minutes, 
and then thoroughly resuspending the cellular components). Plasma viscosity was 
measured at 50 s' 1 (this having previously been found to give optimal sensitivity for 
plasma) on the Haake CV 100 system. This value for plasma viscosity was used as the 
viscosity at zero haemoglobin concentration for all shear rates, assuming that the 
plasma was behaving as a Newtonian fluid (i.e. viscosity independent of shear rate). 
Results are expressed as means ± SD with viscosity measured in mPa sec.
The natural logarithm of the viscosity was plotted against the haemoglobin 
concentration for the 3 shear rates, and the slopes derived for each set of measurements 
[181] (Fig. 30). The slopes of these lines (si 3 s '1, si 30 s"1, and si 300 s"1 
respectively) are sensitive to two major factors. These are (i) the ability of the red 
cells to disaggregate and to streamline under the effect of shear (this reflects the shear 
rate, the forces tending to hold the red cells together, and, particularly at high shear, 
the individual deformability of the red cells); and (ii) the plasma viscosity, as it is both 
a fixed point for the line, and its contribution to the whole blood viscosity decreases with 
increasing haemoglobin concentration. The natural logarithm of the viscosity at a 
calculated haemoglobin concentration of 15 g/dl (In V) was also plotted against the 
natural logarithm of the respective shear rates (In sh) to yield the gradient, In V/ln sh. 
This value reflects the increasing effect of shear forces in being able to disaggregate and 
streamline the red cells in the direction of flow.
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Plasm a (E D TA -an ticoagu la ted ) and serum  v isco s itie s  were determined 
at 37°C using a Luckham (Burgess Hill, UK) capillary viscometer. This system allows a 
greater precision than the Haake CV 100 rotational viscometer for plasma and serum, 
allowing more precise comparison of change in these parameters with time. It is, 
however, not suitable for measuring whole blood viscosity. Results are expressed as 
means ± SD, with values quoted in mPa sec.
Plasma fibrinogen was measured in aliquots of citrated plasma using an assay 
based on the method of Clauss [182]. Results are expressed in mg/dl (normal range 
200-500 mg/dl).
Red cell de fo rm ab ility  was determined in 30 control subjects (Group B), and 
in patient groups 2 and 3 before EPO was started, every subsequent two weeks up to 4 
months of treatment, and thereafter monthly up to 9 months of therapy. This was 
assessed by filtering a red cell suspension through a 5 pm filter [183,184]. Before 
filtration, white cells were removed by adherence in a 5 cm cellulose column (50% a- 
cellulose; 50% microcrystalline cellulose, Sigma Chemicals). Approximately 3-5 ml 
of EDTA-anticoagulated whole blood was loaded onto the column and flushed through with 
phosphate-buffered saline (PBS; pH 7.4). Absence of white cells in the effluent was 
confirmed by analysis on a Technicon (Basingstoke, UK) H1 analyser. The resulting red 
cell suspension was then further diluted in PBS to achieve a final concentration of 
around 5x1011 red cells per litre. The volume of red cell suspension passing through a 
5 pm Hemafil polycarbonate membrane (Nuclepore Corp., Pleasanton, California, USA) 
in 10 seconds under a positive pressure of 5 cm of water was then calculated by 
microcomputer, and compared to the volume of PBS previously passed through the same 
filter. The mean transit time (in msec) per red cell was calculated by analysis of the 
flow curves by the microcomputer controlling the process. Full details of the 
methodology and analysis have been published [183,184].
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A n a ly s is  o f re s u lts
Analysis of variance and the two-tailed paired t test were used to compare results 
at different time intervals. Unpaired t tests were used to analyse the differences in 
results for the control groups versus the dialysis patients prior to EPO therapy. Values 
are expressed throughout as means ± SD for each group.
RESULTS
Haemoglobin response. In all 3 groups of patients the haemoglobin 
concentration rose over the first 4 months of therapy to reach the target range of 10-12 
g/dl (see Chapter 2, Fig. 9). There was no significant difference between the two 
subcutaneously-treated groups and the intravenously-treated group of patients. With 
adjustments in the dose of EPO, the haemoglobin concentration was maintained within the 
target range thereafter. There were no significant changes in the white cell or platelet 
counts after EPO (data not shown).
W hole blood v iscos ity . Whole blood viscosity increased over the first 4 
months of EPO treatment at all 3 shear rates (Fig. 31). As expected, the differences 
were more marked the lower the shear rate (3.16±0.62 to 8.08±1.31 mPa sec (3 s"
1); 2.12±0.29 to 3.83±0.53 mPa sec (30 s"1); and 1.88±0.29 to 2.84±0.22 mPa sec 
(300 s"1). These results represent a 2.6-, 1.8-, and 1.5-fold rise in WBV over the 
first 4 months for the 3, 30, and 300 s' 1 shear rates respectively. Repeat 
measurements at 12 months showed no significant difference from those obtained at 4 
months (Table 7, Fig. 31). When the WBV data are plotted against the values of 
haemoglobin concentration, the relationship can be seen to follow an exponential function 
(Fig. 32) where r = 0.89 at 3 s""1, 0.96 at 30 s'"1, and 0.95 at 300 s '1. Thus, for a 
linear increase in the haemoglobin concentration, there was a disproportionate increase 
in the WBV, most marked the lower the shear rate. Nevertheless, the maximum values 
obtained in this group of patients were still considerably lower than in the normal 
healthy volunteers (Table 7). In the patient group, there were no significant changes in
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the slopes of the shear rates (si 3 s '1, si 30 s '1, and si 300 s"1) measured over the 
first 4 months of therapy, with most values being similar to those in the control group 
(Table 7). The one exception to this was that the dialysis patients before and after EPO 
had slightly greater slopes for the 3 s' 1 shear rate than did the normal volunteers.
When the WBV 300 s' 1 values in the patients were corrected to standard haemoglobin 
concentrations of both 10 and 15 g/dl, they were comparable to the values obtained from 
the healthy volunteer group, except at 12 months when they were slightly higher in the 
patient group (Table 7). This was due to the combination of a marginally higher PV and 
si 300 s' 1 at 12 months compared to baseline, and the difference becoming exaggerated 
due to the logarithmic relationship. The gradient In V/ln sh, however, was consistently 
greater in the EPO-treated patients than in the control subjects at all time-points 
measured (Table 7); this is a consequence of the greater slopes for the 3 s' 1 shear rate 
in the dialysis patients. This difference between the control and patient groups is likely 
to be due, at least in part, to the direct effect of the slightly higher plasma viscosity 
increasing red cell to red cell interactions.
Plasma/serum v iscos ity . There was no significant difference between the 
mean plasma viscosity for the haemodialysis patients before receiving EPO and that for 
the control group of healthy volunteers, both values being within the normal range. No 
significant changes in either plasma or serum viscosity were found during the period of 
study (Fig. 31).
Plasma fibrinogen. Consistent with the lack of change in the plasma viscosity 
results with EPO, no alterations were found in the levels of plasma fibrinogen during the 
first 4 months of therapy, the values obtained remaining within the normal range of 
200-500 mg/dl (Table 7).
Red cell de form ab ility . Although there was some variation in the red cell 
transit time in both groups of patients during the first 9 months of EPO therapy, no
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significant changes in this parameter were found compared to baseline measurements 
(Fig. 33). Likewise there were no significant differences between the results for the 
haemodialysis patients versus the CAPD patients, nor the EPO-treated patients as a 
whole versus the control group of healthy volunteers (Fig. 33).
M CV/MCHC/reticulocyte count. Although in some patients an increase in 
MCV was found in the early stages of therapy, particularly if there was a marked 
reticulocytosis, as a group there were no significant changes in this parameter during 
the period of study (Table 8). One patient, however, had a persistently high MCV 
throughout (100-108 fi), and it was of note that she generally had slower transit times 
than the other patients in the group. There was a slight but progressive decrease in the 
MCHC in both Group 2 and Group 3 patients, reaching significant levels after about 8- 
10 weeks (Table 8). This was thought to be due to the development of early functional 
iron deficiency [123,124,125]. As expected, there was a significant increase in the 
reticulocyte count following EPO therapy of around 2-3 times the pre-treatment value 
(Table 8). This, however, was not manifested in any detectable change in red cell 
deformability.
DISCUSSION
This study represents the first detailed sequential analysis of the rheological 
changes occurring during the correction of renal anaemia with EPO therapy [185]. The 
data presented here confirm the expected increase in whole blood viscosity associated 
with the EPO-induced rise in haemoglobin concentration [160,173]. It is at the lower 
shear rates that the exponential increase in blood viscosity with haemoglobin 
concentration is most apparent, due to an increase in cell to cell interaction and a 
decrease in the streamlining of the red cells seen at high rates of shear. High plasma 
viscosity and elevated red cell aggregation can critically limit blood flow in the 
microcircuiation, while the flow in large blood vessels predominantly depends on the 
haematocrit [178]. The increase in WBV is appropriate for the rise in haemoglobin
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concentration at all stages of treatment, suggesting that it is occurring solely as a result 
of this increase in circulating red cell mass. Consistent with this is the lack of any 
change in the plasma viscosity, or in the rheology of the red cells themselves as assessed 
by their deformability.
Schaefer et al. [173] also reported increases in WBV at low (2 s"1) and high 
(100 s '1) shear rates which did not reach the values seen in healthy subjects. Unlike 
the present study these workers determined WBV in native blood only, and not in 
samples with an adjusted haematocrit. In contrast to the present study, these authors 
reported elevated plasma viscosity measurements and fibrinogen levels in their 
haemodialysis patients prior to EPO [173]. As with the results reported in this study, 
however, Schaefer et al. [173] noted a slight but insignificant rise in these parameters 
after 16 weeks of therapy. Using a controlled stress rheometer, Brunner et al. [186] 
demonstrated a rise in the apparent WBV from 2.52±0.24 to 2.86±0.39 mPa sec 
associated with an increase in the haematocrit from 0.25 before EPO to 0.36 after 12 
weeks' therapy. Determination of apparent WBV curves against different haematocrits, 
however, showed that the increase in WBV after 12 weeks was less than predicted from 
the rise in haematocrit and the initial WBV curve. This contrasts with the findings in 
the present study which indicate that the rise in WBV on repeated measurement up to 16 
weeks correlated very well with what was anticipated from the initial WBV curve. The 
less-than-expected increase in WBV in the study by Brunner et al. [186] was attributed 
to a transient reduction in erythrocyte aggregation seen after correction of the anaemia 
by EPO. Mayer et al. [187], however, obtained data consistent with the results reported 
here in that, when the rise in WBV was corrected for the increase in haematocrit, no 
change in blood viscosity was evident.
Several groups of workers have reported abnormalities of red cell deformability 
in undialysed patients with end-stage renal failure [188,189,190]. Regular dialysis 
treatment, however, restores the red cell deformability to normal [190], consistent 
with the findings in the present study. Although there have been reports of impaired red 
cell filterability in patients undergoing haemodialysis [189,191,192,193,194] or
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CAPD [189], these studies were carried out using erythrocyte suspensions that were 
contaminated with leucocytes, to which filtration is extremely sensitive 
[183,184,195]. In the present study, absence of white cells in the preparation was 
confirmed prior to measurement of erythrocyte deformability. Red cell rheology is also 
affected by changes in the MCV, MCHC, and erythrocyte shape [179,180]; all three of 
these parameters may be abnormal in chronic renal failure.
Lerche et al. [196] studied a number of parameters of red cell rheology in 
haemodialysis patients before, and after 7 and 30 weeks of EPO therapy. These workers 
found significant reductions in the apparent membrane elastic shear modulus and 
capillary rigidometer entry time of red cells (assessed by micropipette aspiration 
techniques), but no change in the red cell aggregation index, Dublett time, or plasma 
viscosity. These techniques, however, assessed only relatively small numbers of 
erythrocytes (about 25-100 cells per sample). A recent study by Koppensteiner et al. 
[197] showed an increase in red cell aggregation in haemodialysis patients treated with 
EPO which was attributed to the increasing number of red cells. Their finding that at 
low shear rate the value exceeded that seen in the control subjects is consistent with the 
data in the present study showing differences in the si 3 s-"1 (see Table 7).
In summary, therefore, a rise in WBV has been universally found following an 
increase in haematocrit with EPO [173,176,186,187]. The results of the present 
study suggest that the progressive increase in WBV can be attributed solely to the 
increased haematocrit, rather than to any changes in erythrocyte rheology or plasma 
viscosity. The discrepancy between the findings documented here and the few reports of 
alterations in red cell deformability [196] or aggregation [186] may be accounted for 
by differences in the methodology used. If, however, changes in red ceil rheology do 
occur with EPO therapy then it would appear that their contribution is too small to have 
a significant effect on WBV, of which haematocrit is the most important single 
determinant [177].
The clinical relevance of these findings remains unclear. Since blood viscosity, 
by mechanisms not completely understood, appears to determine vascular resistance
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[178,198,199,200] and thereby blood pressure [201,202,203], it has been suggested 
that the rise in WBV plays a major role in the pathogenesis of hypertension in patients 
treated with EPO [160,173,176]. Nevertheless, as seen in the present study, the 
absolute values of WBV obtained at the target haemoglobin concentration are still 
considerably lower than those in normal individuals. Furthermore, Steffen et al. [204] 
found no correlation between the changes in WBV and the increases in blood pressure in 
10 haemodialysis patients receiving EPO. Finally, Williams et al. [205] acutely raised 
the haematocrit, and hence the WBV, in 100 haemodialysis patients by transfusion, and 
found no significant increase in blood pressure. Similarly, there was no evidence of a 
pressor effect in 100 CAPD patients in whom a spontaneous rise in haemoglobin 
concentration was observed within the first 12 months of commencing dialysis [205].
The contribution of the EPO-induced rise in WBV to the increased risk of 
developing thrombotic side-effects, particularly of the arteriovenous fistula 
[90,92,93,174,175], is also uncertain. An increase in blood viscosity to supra- 
normal levels, however, is associated with frequent thrombotic events in patients with 
polycythaemia or Waldenstrom's macroglobulinaemia. Other factors, such as alterations 
in platelet function [206,207,208,209] or a reduction in protein C and protein S 
levels (see Chapter 5) [210] after EPO therapy may also contribute. On a more positive 
note, the increase in WBV associated with EPO may play a role in the reversal of erectile 
impotence reported in male haemodialysis patients after EPO therapy [211].
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CHAPTER 5
FISTULA BLOOD FLOW AND COAGULATION STUDIES DURING
ERYTHROPOIETIN THERAPY
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INTRODUCTION
Hypertension [1,2,3,4,90,91,92,93,173] and thrombosis of the arteriovenous 
fistula [90,92,93,174,175] are the two most worrying complications of EPO therapy 
in haemodialysis patients. Many of the early studies on EPO produced anecdotal reports 
of this latter problem developing in treated patients [90,92,93], and this was followed 
by results from a European multi-centre trial involving 150 haemodialysis patients 
which recorded an incidence of fistula thrombosis of 9-10% [174]. Clotting in the 
extra-corporeal circuit was found in a similar proportion of patients [174]. More 
recently a placebo-controlled multi-centre trial from Canada showed a significantly 
higher incidence of fistula thrombosis in patients treated with EPO (11 of 78 patients) 
compared to those given placebo (1 of 40 patients) [175]. Whether other thrombotic 
complications such as myocardial infarction and stroke occur more commonly than in 
untreated haemodialysis patients is as yet unknown.
Both the hypertension and the thrombotic complications do not appear to be 
related to the EPO per se; rather this has been attributed to the resultant increase in 
haematocrit and associated rise in blood viscosity (see Chapter 4) [160,173,185]. 
Other factors, however, may contribute to an enhanced risk of fistula thrombosis. 
Bleeding time is corrected or improved in the majority of patients on EPO therapy 
[185,206]. Changes in platelet function have also been reported [206,207,208,209]. 
Nevertheless, there have been no comprehensive studies published on the effect of EPO 
on the haemostatic system as a whole. This was the aim of the present study which 
monitored a variety of coagulation tests over the first few months of EPO therapy in 10 
haemodialysis patients. In addition, fistula blood flow was measured by ultrasound using 
the Doppler technique.
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PATIENTS 
Group 1
Ten stable patients maintained on chronic haemodialysis were studied. Their 
demographic details including age, sex, aetiology of renal disease, duration on dialysis, 
and starting haemoglobin concentration are all as documented in Chapter 4 (Group 1 
patients). One patient (34 years, female) had suffered 2 previous myocardial 
infarctions during the preceding 2 years and had subsequently undergone a right 
coronary angioplasty; another patient (75 years, male) had a past history of recurrent 
transient ischaemic attacks, and a further 2 patients had sustained previous thrombosis 
of their arteriovenous fistulae. Three of the patients were regular cigarette smokers. 
None of the patients received anticoagulant therapy except heparin during dialysis, and 
none had clinical or laboratory evidence of liver disease.
All patients were treated with EPO (Boehringer Mannheim GmbH, Germany) 120 
U/kg given intravenously (IV) twice weekly at the end of dialysis. While receiving EPO 
therapy, 2 patients developed fistula thrombosis: in one (51 years, female), occurring 
at 13 weeks, blood flow was regained almost immediately following a sharp external 
blow to the fistula; in the other (22 years, male) surgical recanalisation was 
unsuccessful and a new fistula had to be constructed. No other thrombotic events were 
encountered during the first 12 months of EPO therapy.
Group 2
Protein C and protein S levels were monitored in a further 12 stable 
haemodialysis patients (6 males, 6 females; mean age = 37±18 years) who had been 
receiving regular dialysis for a mean of 2.5±2.3(SD) years. The cause of their renal 
disease was chronic pyelonephritis/reflux nephropathy (4 patients), interstitial 
nephritis (1 patient), lupus nephritis (1 patient), IgA nephropathy (1 patient), 
obstructive uropathy (1 patient), and polycystic kidney disease (1 patient), with three 
patients undiagnosed.
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The mean haemoglobin concentration immediately before starting EPO ranged 
from 6.0 to 7.8 g/dl (mean 6.8 g/dl) and serum ferritin, B12, and folate levels were as 
for the first group. The patients in this second group were treated with a starting dose of 
60 U/kg of EPO (Boehringer Mannheim GmbH, Germany) administered subcutaneously 
(SC) twice weekly. None of these patients developed fistula clotting or any other 
thrombotic complications over the first 6 months of EPO therapy.
METHODS
All tests were carried out, and all samples taken, immediately prior to a dialysis 
session.
Haemoglobin concentration was measured weekly on a Technicon (Basingstoke, 
UK) H1 automated analyser up to 4 months of treatment, and measured monthly 
thereafter. Whole blood viscosity (WBV) was measured every 2 weeks up to 4 months of 
EPO therapy, and again at 12 months (results reported in Chapter 4). Bleeding time 
was determined every 2 weeks up to 4 months of EPO, and again at 12 months using the 
Simplate Bleeding Time Device on the non-fistula forearm.
The following tests of coagulation and/or haemostasis were determined on blood 
anticoagulated with sodium citrate 0.105 M (1 part citrate : 9 parts blood) every 2 
weeks up to 4 months of EPO therapy: one-stage prothrombin time (OSPT), kaolin 
cephalin clotting time (KCCT), and whole blood clotting time (WBCT). All were 
measured using standard methods, and the prothrombin consumption index (PCI) 
calculated. Factor VII and factor VIII levels in plasma were measured by an optical 
density method using the Coag-A-Mate XC (Organon Teknika Ltd., Cambridge, UK) 
system. Plasma fibrinogen levels were determined using an assay based on the method of 
Clauss [182], again utilising the Coag-A-Mate XC system. Anti-thrombin ill levels 
were measured using a chromogenic assay. Protein C and protein S (total and free) 
levels were measured by ELISA using commercially available kits (Boehringer 
Mannheim GmbH, Germany). Platelet aggregability was measured in platelet-rich 
plasma after dilution to a standard count of 120-150x109/l by means of impedance
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aggregometry using ADP as the aggregating agent. A dose-response curve to increasing 
concentrations of ADP (1x10-7 to 5x10-5 M) was constructed at each assessment, and 
the peak of aggregation was measured in millimetres.
Fistula blood flow was measured before EPO therapy, and after 1, 2, 3, 4, and 12 
months of treatment by means of ultrasonography on a Toshiba Sonolayer SSA-100A 
system (Crawley, West Sussex, UK) using the Doppler technique. The average of three 
measurements was taken on each occasion, and results were expressed in litres per 
minute. The same operator performed the test throughout the study, and care was taken 
to use the same site for each assessment.
Analysis of variance and two-tailed paired t tests were used to analyse the 
statistical significance of any changes in the above parameters during EPO therapy.
RESULTS
Haemoglobin concentration
The rise in haemoglobin concentration (Hb) for both groups of patients is shown 
in Fig. 34. Both groups had fairly similar Hb responses despite the fact that the group 
treated IV received twice the dose of EPO compared to the group treated SC. Doses of EPO 
were adjusted to achieve or maintain a target Hb of 10-12 g/dl.
Coagulation/haemostasis tests
Seven of 10 patients had bleeding times greater than 30 minutes prior to EPO 
therapy (Table 9). This improved in 4 of these patients after 6 weeks, and by 16 weeks 
nine patients had a normal bleeding time (less than 10 minutes) and one patient had a 
borderline measurement. This improvement in bleeding time was still present at 12 
months.
Platelet aggregability, one-stage prothrombin time, kaolin cephalin clotting 
time, whole blood clotting time, and prothrombin consumption index were all found to be 
within the normal range prior to EPO therapy, and no significant changes were noted 
during the first 4 months of treatment. Plasma fibrinogen levels were normal
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throughout the first 4 months of EPO, consistent with the normal plasma viscosity 
results. Likewise, factor VII, factor VIII, and anti-thrombin III levels in plasma did not 
change with EPO therapy (Table 10).
Protein C and Protein S
Two baseline measurements of protein C obtained from group 1 patients were 
both within the normal range of 80-120% , the mean value immediately prior to 
treatment being 84.3±8.2% (Fig. 35). Levels of protein C remained unchanged during 
the first 2 months of EPO therapy but by 3 months there was a significant fall in protein 
C which by 4 months had reached levels (66.4±12.5%) thought to predispose to 
thrombosis (less than 70% [212,213]). After 8 months of EPO, however, protein C 
levels had returned to baseline values and this was maintained on re-testing at 12 
months (85.4±17.0%). A similar fall in protein C levels was seen in the group 2 
patients. Again, a significant reduction in protein C was found after 4 months of EPO 
therapy (Fig. 35).
Total protein S levels in group 1 patients began to fall after 1 month of EPO 
therapy having been in the upper end of the normal range on two occasions prior to EPO 
(mean value immediately prior to treatment: 124.1 ±24.3%) (Fig. 36). By 2 months a 
significant reduction was evident, and levels of protein S measured at 4 months 
(68.3±15.1%) were in the range believed to predispose to thrombotic complications 
(less than 70% [212,213]). As for protein C, protein S levels had returned to baseline 
by 8 and 12 months (118.1 ±32.8% and 107.9±23.7% respectively). A similar 
incremental fall in the concentrations of free protein S was found which paralleled the 
decrease in total protein S levels (61.5±25.6% pre-EPO; 37.1 ±10.6% at 4 months; 
55.8±21.4% at 12 months) (Fig. 36). These results were confirmed in the second 
study on group 2 patients in which reductions in both total and free protein S were again 
observed (Fig. 36).
To elucidate whether this effect was directly related to EPO perse  or to the 
correction of anaemia, a limited study was performed in an additional 5 anaemic
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haemodialysis patients in whom protein C and protein S levels were measured before (2 
measurements) and after (2 measurements) 4 units of packed cells. The mean Hb rose 
from 6.3±1.0 (SD) g/dl to 11.0±1.0 g/dl which is comparable to the increase seen in 
the EPO-treated patients. However, no alterations in protein C or protein S levels were 
observed with this acute correction of renal anaemia (protein C: 76.6±15.3% to 
76.8±13.6%; total protein S: 104.8±16.6% to 102.2±13.2%; free protein S: 
39.6±5.7% to 39.2±5.4%). In contrast, in a 64-year-old non-renal patient with iron 
deficiency anaemia who was treated with oral ferrous sulphate, protein C levels fell 
from 79% to 67% and total protein S levels fell from 101% to 72% (free protein S: 
33% to 21%) over a 10-week period during which his haemoglobin rose from 4.9 to 
9.9 g/dl.
F is tu la  b lo o d  f l o w
There was no significant change in fistula blood flow over the first 4 months of 
EPO treatment (Table 10). At 12 months, this showed a tendency to increase but results 
were not statistically significant.
DISCUSSION
The results presented here show a marked reduction in both protein C and protein 
S levels in two groups of haemodialysis patients treated with EPO. It is well-established 
that protein C and protein S are important endogenous inhibitors of coagulation in 
plasma, being synthesised in the liver by vitamin K-dependent mechanisms 
[213,214,215,216,217]. The inactive precursor of protein C is converted to the 
active protease by thrombin and an endothelial cell-associated cofactor called 
thrombomodulin [218]. Activated protein C has a potent anticoagulant effect by 
inactivating factors V and VIII [214] and stimulating the fibrinolytic system [219]. 
Protein S acts as a cofactor by enhancing the rate of inactivation of factors Va and Villa 
by protein C. It has been postulated that this is effected by promoting the binding of 
protein C to phospholipid [220]. Protein S exists in two forms in plasma: 60% is bound
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to the complement component C4b-binding protein, and the remainder is free. Only the 
latter fraction appears to be active [221].
Both congenital and acquired protein C deficiencies are associated with a 
thrombotic tendency [222,223,224,225]. More recently, protein S deficiency has also 
been discovered to predispose to thrombotic events [221]. The levels of protein C and 
protein S obtained after 4 months of EPO therapy in this study are comparable to those 
levels known to promote thrombosis [212,213]. It is possible, therefore, that the 
higher-than-expected incidence of fistula thrombosis in patients receiving EPO may be 
in part related to the reduction in levels of these natural anticoagulants during the first 
few months of therapy. Consistent with this is the observation that clotting of the fistula 
usually occurs early in the course of EPO therapy. It is also interesting that the two 
patients in this study who thrombosed their fistulae did so when their protein C and 
protein S levels were at their lowest, and furthermore that these two patients had the 
greatest falls in these factors.
Whether the reduction in protein C and protein S is a direct effect of the EPO per 
se or whether it is a consequence of the correction of anaemia is still not clear. There 
was no change in either protein C or protein S levels after acute correction of renal 
anaemia by transfusion in this study. However, in the non-renal patient with iron 
deficiency anaemia who had a more gradual rise in haemoglobin concentration with iron 
therapy, there appeared to be a significant fall in both protein C and protein S. It is, 
therefore, possible that slow amelioration of anaemia results in a transient fall in levels 
of protein G and protein S which is not seen with more rapid correction. Further 
evidence against a direct effect of EPO is found in one patient who had a poor haemoglobin 
response to EPO and latterly had to be withdrawn from the study due to gastrointestinal 
bleeding. She showed no change in her protein C or protein S levels over 4 months 
despite receiving higher doses of EPO than the other patients in this study. Although 
results from this one patient have to be interpreted with caution, this again is consistent 
with a hypothesis that the EPO-induced reduction in protein C and protein S occurs
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secondarily to the improvement in anaemia rather than to the EPO therapy itself. The 
exact mechanism by which this occurs, however, is uncertain at the present time.
Uraemic patients on long-term haemodialysis are prone to both a bleeding 
tendency and a hypercoagulable state [226,227,228,229]. This paradoxical association 
is not clearly understood, but several studies have sought to elucidate this by 
investigating the role of platelets and platelet function [226,227], coagulation factors 
[230], the fibrinolytic system [228], anti-thrombin III [231,232,233], factor VIII 
complex [229], and protein C [234,235]. The results of these studies, however, are 
confusing. Sorensen et al. [234] found depressed protein C activity in 14 haemodialysis 
patients compared to age- and sex-matched controls. In a later study, the same group 
confirmed their earlier results, but found normal protein C antigen levels in 10 
haemodialysis patients [235], consistent with the results obtained from the patients in 
the present study prior to EPO therapy. They postulated that one or more inhibitors of 
protein C activity may be present in uraemic plasma.
The striking improvement in bleeding time reported here confirms the earlier 
findings of Moia et al. [206], and shows in addition that this improvement is maintained 
in the long-term. The exact mechanism for this effect is not yet fully elucidated, but it 
seems clear that the presence of adequate numbers of red cells are required for normal 
platelet function [236],
It was reassuring to find no reduction in fistula blood flow over the first 12 
months of EPO therapy despite a significant increase in whole blood viscosity. 
Nevertheless, in none of the patients were any pre-existent stenotic areas identified 
which might be expected to lead to thrombotic problems in the presence of a greater 
blood viscosity. More disappointing was the apparent inability of the Doppler ultrasound 
technique to predict an impending fistula thrombosis in the two patients in which this 
occurred. Both patients had had an assessment of their fistula only 1-2 weeks prior to 
its occlusion, and there was no hint of any reduction in blood flow. This suggests that the 
occlusion happened fairly rapidly, rather than developing gradually in a slowly 
worsening stenosis.
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Whether prophylactic anti-thrombotic measures are warranted in haemodialysis 
patients receiving EPO remains uncertain, although there are theoretical reasons for 
using an anti-platelet agent in those at high risk because of other factors [237].
Further studies will be required to elucidate the exact mechanism of the reduction in 
protein C and protein S levels in patients receiving EPO, and the role this has in 
predisposing to thrombosis.
Table 9 Effect of EPO on bleeding time in 10 haemodialysis patients treated with 
an initial dose of 240 U/kg/wk IV
PATIENT Pre-EPO +6 wks +16 wks +1 yr
SW 1 2 1 2 6 5
HL 30 + 7 3 6
BB 30 + 1 2 6 6
RP 30 + 30 + 1 1 8
EE 7 4 4 5
SR 30 + 30 + 6 1 1
AF 30 + 14 6 6
CL 1 3 4 6 6
A3 30 + 13 9 5
YJ 30 + 30 6 6
Results expressed in mins (normal <10 mins). 
30+ = greater than 30 mins.
(NB: SR on dipyridamole throughout).
Table 10 Haemostatic parameters and fistula blood flow measured in 10 
haemodialysis patients during EPO therapy
Time (weeks
0 4 8 12 16
OSPT (secs) 16.5 (1.3) 16.2 (1-3) 16.5 (1.1) 14.9 (1 .1) 15.5 (0.5)
KCCT (secs) 38.9 (2.4) 38.1 (3.2) 37.4 (2.9) 38.4 (3.2) 38.3 (3.9)
WBCT (mins) 7.5 (2 .2) 6.9 (0 .8) 6.6 (1.9) 6.7 (1.7) 6.9 (1.3)
PCI (%) 19.6 (11.1) 15.0 (11.5) 16.6 (7.8) 16.6 (11 .8) 21.3 (15.0)
Fibrinogen (mg/dl) 276 (44) 326 (83) 296 (52) 304 (65) 298 (72)
Factor VII (%) 147 (31) 150 (43) 113 (18) 164 (31) 145 (19)
Factor VIII (%) 101 (42) 115 (27) 120 (38) 134 (31) 115 (27)
AT III (%) 102 (13) 103 (17) 107 (26) 105 (27) 87 (8)
Platelet
aggregability
5x10-7 M 0.1 (0.4) 0 (0) 0 (0) 0.8 (1.4) 0 (0)
5x10-6 M 21.1 (17.6) 17.3 (13.2) 0.3 (0.7) 5.9 (10.9) 20.4 (10.0)
to ADP (mm)
5x10*5 M 32.4 (15.3) 30.0 (7.2) 28.5 (16.3) 16.8 (12.3) 25.8 (11.4)
Fistula blood flow (l/min) 1.02 (0.35) 1.03 (0.28) 1.06 (0.30) 1.08 (0.31) 1.09 (0.23) 
[1.42 (0.44) 
at 12 mthsl
Results expressed as means (SD).
OSPT = one-stage prothrombin time
KCCT = kaolin cephalin clotting time
WBCT = whole blood clotting time
PCI = prothrombin consumption index
AT III = anti-thrombin III levels
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Fig. 34 Mean haemoglobin response to EPO therapy in 2 groups of haemodialysis 
patients:-
Group 1 treated with 240 U/kg/wk of EPO given intravenously.
Group 2 treated with 120 U/kg/wk of EPO given subcutaneously.
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CHAPTER 6
STUDIES USING 125|-LABELLED RECOMBINANT HUMAN
ERYTHROPOIETIN
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INTRODUCTION
The studies described in the previous chapters of this thesis sought to elucidate 
the biological effects of amelioration of renal anaemia with recombinant EPO in dialysis 
patients. In the present chapter, a number of studies are described which make use of 
125 iodine-labelled EPO as a tool for examining the metabolic fate of erythropoietin, 
along with the absorption kinetics of subcutaneously-administered EPO.
Details of the labelling procedure are given in full, and some of the problems 
encountered with interpreting the subsequent behaviour of the radiolabelled product are 
also described. Before conducting detailed studies with 125l-EPO, it was clearly 
necessary to show that it had the same structural and biological characteristics as 
unlabelled EPO. Thus, chromatographic and electrophoretic techniques, along with a 
standard bioassay, were used to analyse the labelled material.
There are several theoretical advantages in using a radiolabelled preparation of 
EPO. Firstly, it is relatively quick and easy to calculate pharmacokinetic parameters 
following an IV bolus injection by measuring serial counts of activity in the plasma or 
serum. Assessing urinary counts gives information on renal handling and clearance, and 
by performing chromatographic analysis of the serum samples it is possible to look for 
metabolites of EPO which might retain radioactivity but be non-immunoreactive. 
Furthermore, in the second study, using radiolabelled EPO allowed the disappearance of 
the drug from subcutaneous injection sites to be monitored by means of an external 
gamma counter. This could be correlated with the appearance of counts in the 
bloodstream, and comparisons made between different injection sites.
The chapter is divided into 3 main sections:-
( i ) Labelling of EPO with 125iodine.
( i i )  Kinetics and clearance of intravenously-administered **25 l-labelled EPO in 
healthy volunteers.
( i i i )  Absorption kinetics and bioavailability of subcutaneously-administered 125 l- 
labelled EPO: comparison of three different sites of injection.
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( i )  L a be l l ing  o f  EPO w i th  1 25 io d in e
The chloramine-T method has been used widely in the past for labelling proteins 
with radioactive iodine [238]. In order to be able to perform the studies described 
later, this method was therefore used for labelling EPO with 125 iodine. Various 
chromatographic and electrophoretic tests were carried out to characterise the nature of 
the radiolabelled material, and its bioactivity was confirmed by the polycythaemic 
mouse bioassay.
Methods & Results
C hloram ine-T method: 50 pi of chloramine-T (0.5 mg/ml) (Sigma Chemical Co.
Ltd., Poole, Dorset, UK) in 0.05 M phosphate-buffered saline (PBS) was added to 25 pg 
of carrier-free recombinant EPO, kindly supplied by Boehringer Mannheim GmbH, 
Germany. To this was added 10 jxl of Na 125l (100 mCi/ml; Amersham, 
Buckinghamshire, UK), i.e. 1 mCi or 37 MBq of radioactivity. The solution was mixed 
well for 30 seconds, and the reaction was then stopped by 100 pJ of sodium 
metabisulphite (2 mg/ml) in PBS. At this point, 100 p.! of 10 mg/ml potassium iodide 
was added as a carrier, followed by 200 pJ of 2% human serum albumin.
Separation of 25 l-labelled EPO from unreacted 1 ^ iod ide  was carried out using 
a 10 cm Biogel P60 desalting column (Bio-Rad, Thetford, Essex, UK). The column was 
primed using 2-3 ml of 2% human serum albumin (CIS UK Ltd., High Wycombe, UK) to
reduce adsorption, and 0.5-1.0 ml of 125 l-labelled material was then loaded onto it and
eluted with PBS. 1 ml fractions of elute were collected into 4 ml polystyrene tubes 
every 1-2 minutes, and the column run until both the 125 l-labelled EPO and free 
125iodide peaks had been eluted. The radioactivity in all fractions was measured, and 
the fraction containing the highest activity from the earlier peak was retained for
further use; this generally eluted at about 4-5 ml.
The percentage yield was calculated from the activity in the tube divided by the 
initial activity introduced into the system (37 MBq), and multiplied by 100%. This
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was generally found to be between 60 and 70%, and the specific activity of the 
radiolabelled material was usually around 1 MBq/jig of protein. Thus the end-result of 
the procedure was a fairly "light” labelling of approximately 1 atom per molecule of EPO 
in order to minimise the potential damage to the protein structure.
The 125 l-labelled material was then subjected to:-
a ) Gel permeation chrom atography using a G75 Sephadex column (Pharmacia, 
Milton Keynes, UK) measuring 1 metre in length. Both phosphate-buffered 
saline and sodium dodecyl sulphate (SDS) were used to elute the sample. The void 
volume (V0) for the column was 32 ml and the Vt was 88 ml. 2 ml fractions of 
the elute were collected at a rate of 5 fractions per hour for 24 hours. The 
fractions were then counted on a gamma counter and the total counts per minute 
(cpm) in each fraction determined. The elution profile of level of radioactivity 
versus elution volume was then constructed. Fig. 37 shows a representative 
elution profile for the 125 l-labelled material run in PBS. Three peaks were 
obtained and previous calibration curves for this column suggested that the 
second peak (which constituted approximately 95% of the total activity) 
correlated with the known molecular weight of native EPO (30,400 daltons).
The third peak represented residual free 125 iodine, but the nature of the higher 
molecular weight first peak (which constituted <5% of the total activity) was 
uncertain. The possibilities were that it represented a dimer of EPO (since its 
molecular weight corresponded to approximately 60,000 daltons), or EPO bound 
to some other substance. This phenomenon has been described in previous studies 
[72,239], and Sherwood et al. [239] have suggested that the first peak 
represents dimeric 125l-labelled EPO. This peak was not present when the 
radiolabelled material was run in the same column using SDS (Fig. 38). This 
suggests that the binding of EPO either to itself or another substance is fairly 
loose and is easily abolished by SDS, again consistent with ionic- or 
hydrophobic-bound dimeric EPO. Spivak & Hogans [82] similarly found that
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when EPO was labelled with 125iodine using the lactoperoxidase technique, a 
single band of radiolabelled protein was obtained when analysed by either 
electrophoresis in SDS-urea/7.5% polyacrylamide tube gels or 12.5% SDS- 
polyacrylamide slab gels.
Another problem encountered during the column work was the recovery of 
radiolabelled material in the eluate. This was as low as 31-58% (mean 42.6%) 
when the 125 l-EPO was dissolved in PBS alone, but if dissolved in human serum 
to provide additional carrier protein, the recovery increased to 89-99% (mean 
94.7%). This is almost certainly due to the fact that much of the 125l-EPO was 
adsorbed on the glass tube unless sufficient carrier protein was present. The 
likely explanation for this is the extreme hydrophobicity of EPO as described 
earlier (see Literature Survey, section 4: Biochemistry and physiology of 
erythropoietin).
b )  S D S -p o lyacry lam ide  ge l e le c trop h o res is . The electrophoretic mobility of 
the radiolabelied material in a 12% gel is shown in Fig. 39 and is compared with 
that of a number of protein standards of known molecular weights. More than 
98% of the ",25 l-labelled material was concentrated in a single band occurring 
between carbonic anhydrase (MW 30,000 daltons) and ovalbumin (MW 43,000 
daltons), and this again is consistent with the known molecular size of native 
EPO.
( i i ) K in e t ic s  a nd  c le a ra n c e  o f in t ra v e n o u s ly -a d m in is te re d  1 2 5 l- la b e lle d  
EPO in h e a lth y  v o lu n te e rs
Previous pharmacokinetic studies as described in Chapter 1 and elsewhere
[77,105,108,240] suggest that EPO clearance conforms to a one- or two-compartment
model. There is, however, virtually no information on the metabolism of the
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intravenously-administered recombinant hormone [71]. This was therefore studied in a 
group of normal healthy subjects.
The EPO was labelled with 125| as described above. Six normal healthy 
volunteers (3 males, 3 females; age range 23-44 years) drawn from the hospital staff 
were studied. Each was given an injection of 1 MBq as a single intravenous bolus. All 
subjects took oral potassium iodide, 60 mg daily for 7 days, commencing 24 hours prior 
to injection in order to block thyroid uptake o f 125 iodine. Blood samples were taken at 
0, 15, 30 and 45 minutes, and 1, 2, 3, 4, 6 , 8, 12, 18, 24, 36, 48, 60, 72, and 96 
hours. Eight 12-hour urine collections were obtained over this 4-day period in order 
to determine urinary clearance of EPO. Both serum and urine samples were assayed for 
protein-bound and free iodide counts.
The serum protein-bound activity curve was plotted on a semi-log scale against 
time (Fig. 40). Analysis of this curve suggested three exponential phases (alpha, beta, 
and gamma) with mean (±SD) half-lives of 1.48±0.19, 3.52±0.27, and 26.3±3.1 
hours, respectively. More than 95% of circulating counts were protein-bound. Urine 
analysis showed that there was a negligible excretion of protein-bound counts. The 
apparent volume of distribution was 9.48±1.18 litres.
The half-life data in this study were quite different from previous 
pharmacokinetic studies of EPO [77,105,108,240]. This is likely to be due to the 
presence of dimeric EPO produced by the labelling procedure. Further evidence for this 
is shown in Fig. 41 in which gel permeation chromatography of serum from one of the 
subjects was carried out for the samples at 0.5, 6, 12, 24, and 48 hours. This shows a 
much more rapid decay of the peak 2 activity which would be consistent with monomeric 
EPO, in contrast to peak 1 activity (dimeric EPO) which declined more slowly and thus 
assumed a much greater proportionate representation of the total serum activity. The 
gamma phase in this study therefore seems likely to be due to the persistence of the 
slowly-cleared higher molecular weight peak 1 activity in serum, which was probably 
an EPO dimer.
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Since there has been no gamma phase reported in any of the pharmacokinetic 
studies in which EPO has been measured by radioimmunoassay, it would appear that this 
putative dimer is non-immunoreactive. The lack of any additional peaks in the elution 
profile suggests that there is no further aggregation of EPO in the bloodstream, nor is 
there any evidence of smaller molecular weight metabolites of EPO. What is not clear 
from this study is whether EPO exists as a dimer under physiological conditions or 
whether this has occurred as a consequence of the labelling procedure. It is also 
uncertain whether there is a dynamic equilibrium between dimeric and monomeric 
labelled EPO in the circulation. Since there is no evidence in this study of EPO 
metabolites in circulation, it is possible that the plasma elimination of EPO occurs as a 
consequence of tissue or organ uptake of the hormone rather than by true catabolism of 
EPO.
( i i i ) Absorption kinetics and bioavailability of subcutaneously-
administered 125 l-labelled EPO: comparison of three different 
sites of inject ion
The data presented in Chapter 2 suggest that the subcutaneous route for 
administering EPO may confer several advantages over the IV route. Other published 
work also indicates that the SC route is rapidly gaining popularity as the preferred route 
of administration in both haemodialysis and CAPD patients [114,115,127,128]. There 
is, however, no information as to which is the optimum site for injecting SC EPO. It has 
previously been shown that absorption of subcutaneous insulin was fastest from the 
abdomen, intermediate from the arm, and slowest from the thigh [241,242]. In view of 
the cost of EPO, even small differences in bioavailability between different injection 
sites may result in considerable saving.
The aim of the present study was to compare the absorption kinetics and 
bioavailability of "125l-labeiled EPO injected subcutaneously into the upper arm, the 
abdomen, and the thigh in normal healthy volunteers.
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Subjects and Methods
Eight subjects (4 males, 4 females; mean age 30±5(SD) years; mean weight 
68±14 kg) were studied. Bulkware EPO (Boehringer Mannheim GmbH), which was free 
from stabilising and solubilising agents, was labelled with 125l using the chloramine-T 
method as described earlier. All subjects took oral potassium iodide, 60 mg daily for 7 
days, commencing 24 hours prior to injection in order to block thyroid uptake of 12^l. 
0.5 MBq of 125 l-EPO was then injected SC into the upper arm (mid-deltoid region), the 
abdomen, and the thigh by the same operator on 3 occasions, separated by at least 10 
days. Absorption of 125 l-EPO was monitored in two ways: (i) by its disappearance 
from the site of injection using an external gamma counter, and (ii) by its appearance in 
the bloodstream. Blood samples were taken at 0, 1, 2, 4, 8 , 12, 18, 24, 36, 48, 72, 
and 96 hours after injection, and protein-bound counts determined using a resin which 
adsorbs free iodide. The thickness of the subcutaneous tissue at each injection site was 
measured by ultrasound on a Toshiba Sonolayer SSA-100A system (Crawley, West 
Sussex, UK) in order to correlate bioavailability with the degree of SC fat.
Results
The radioactivity monitored externally over the injection site diminished more 
rapidly following injection into the thigh than for the other two sites (Fig. 42). The 
disappearance profiles for the arm and abdomen were comparable. After 4 days, 
significantly less 125l-EPO remained in the subcutaneous tissue after thigh injection 
compared to the other two sites (Fig. 42, Table 11).
Serum counts (cpm per 1 ml of serum) rose faster after injection into the thigh 
than for the arm or abdomen (Fig. 43). Mean peak levels were nearly twice as high for 
the thigh as for the other two sites (Table 11). The time taken to reach peak blood levels 
was somewhat variable among subjects, and overall there was no significant difference 
between the three injection sites. Likewise, the subsequent elimination from the plasma 
compartment was fairly comparable for all three sites. The area under the curve (AUC) 
to 96 hours for the serum profile following thigh injection, however, was significantly
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greater than for the arm (p<0.01) and abdomen (p<0.005). When the AUC was 
extrapolated to infinity, however, the difference between the thigh and the arm became 
less marked, both sites being superior to the abdomen (Table 11). Although there was 
some variability in the thickness of subcutaneous tissue both between subjects, and 
between different sites in the same subject (Fig. 44), there was no significant 
correlation between the SC tissue thickness and the bioavailability (Fig. 45).
Discussion
Despite increasing usage of the subcutaneous route for administering EPO 
[114,115,116,127,128], no studies have been published which compare different 
sites of SC injection. The results of the present study, which although conducted in 
normal healthy volunteers rather than patients, suggest that the thigh may be the 
optimal site of injection. Absorption from this site was more rapid, and higher peak 
serum levels and bioavailability were obtained. This is in striking contrast to what has 
been previously reported for subcutaneous insulin where absorption was faster for the 
abdomen than for the arm, which was, in turn, faster than the thigh [241,242]. The 
possible reasons for this discrepancy are not clear at the present time, although EPO is 
very different in molecular size and composition to insulin, being larger and more 
heavily glycosylated. Also, the mobility of the subjects in our study was probably 
greater than for those used in the insulin studies. It is likely that exercising the lower 
limb, by increasing regional blood flow, would improve absorption from subcutaneous 
tissue. No restriction was put on our subjects as far as exercise was concerned; they 
were instructed to carry out their daily activities as usual. It is possible, however, that 
EPO-treated patients would be less fit, and have correspondingly lower rates of 
absorption from the thigh, but this requires validation.
In conclusion, on the basis of these preliminary results, the optimal site for SC 
administration of EPO may be the thigh. Further studies, however, are required to 
confirm this, particularly in patients receiving haemodialysis or CAPD.
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Fig. 38 Elution profile o f 125 l-labelled EPO eluted in sodium dodecyl sulphate 
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Fig. 39 Polyacrylamide gel electrophoresis of 125l-labelled EPO in sodium
dodecyl sulphate.
Left-hand strip shows calibration bands of a number of protein standards 
of known molecular weights (in daltons) as shown.
Right-hand strip shows a dense band of 125l-labelled EPO lying between 
carbonic anhydrase and ovalbumin.
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Fig. 40 Serum 125|.|abe||ec| EPO profile following IV injection of 1 MBq to 
6 normal healthy volunteers.
Results are shown both as total counts per minute (cpm) and protein- 
bound (PBI) cpm in 1 ml samples of serum, and are expressed as 
means ± SD.
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Fig. 42 Comparison of disappearance of radioactivity from 3 subcutaneous sites 
following injection of 0.5 MBq i25|_|abe||eci EPO.
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CHAPTER 7
TREATING RENAL ANAEMIA WITH RECOMBINANT HUMAN 
ERYTHROPOIETIN : PRACTICAL GUIDELINES AND A CLINICAL
ALGORITHM
1 0 0
INTRODUCTION
Recombinant human erythropoietin is of proven benefit in the treatment of renal 
anaemia [1,2,3,4] and numerous clinical trials have indicated an acceptable degree of 
safety [90,91,92,93,159]. It has recently been licensed for use in the United States of 
America and several European countries including the United Kingdom. Thus the drug is 
now widely available, prompting the need for practical guidelines to ensure that patients 
receive maximal benefit with the least risk and greatest cost-efficiency.
Based on the author's own experience in treating 42 patients as well as on 
published studies, the following recommendations have been compiled together with a 
clinical algorithm as a guide for the management of patients receiving erythropoietin 
therapy. This chapter considers which patients should be treated, the optimal starting 
dose and route of administration, the monitoring of iron status, target haemoglobin 
concentration, the rate of response, and the investigation of an impaired response, as 
well as potential complications.
Which patients should receive erythropoietin therapy?
It remains uncertain exactly how many dialysis patients would benefit from EPO 
therapy, but estimates of between 50 and 75% have been made [2,3]. Since the 
treatment is both expensive and long-term, careful consideration has to be given to the 
selection of appropriate patients.
As there is often a rise in haematocrit after starting dialysis [28], particularly 
with CAPD [20,41], it is wise to wait at least three months after commencing renal 
replacement therapy before considering erythropoietin. Furthermore, if the patient is 
likely to receive a live donor transplant in the near future, EPO treatment might not be 
warranted. The avoidance of blood transfusion with EPO, however, may justify its use in 
this context by preventing cytotoxic antibody formation and hence improving the chances 
of a successful graft outcome. Patients with a haemoglobin concentration of greater than 
10 g/dl are unlikely to have a noticeable improvement in well-being and have a higher 
chance of side-effects, since whole blood viscosity rises rapidly with higher levels of
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haematocrit (see Chapter 4) [173,185,187]. Thus only uraemic patients with 
haemoglobin concentrations less than 10 g/dl should be considered for treatment.
It is important to exclude other causes of anaemia such as haematinic deficiency, 
blood loss, haemolysis, infection, aluminium toxicity, and malignancy. Any such 
disorder should be corrected and the haemoglobin response assessed before considering 
EPO therapy. In the absence of any other cause, patients with a haemoglobin 
concentration below 8 g/dl will almost certainly benefit from treatment. Those with a 
haemoglobin concentration of 8 to 10 g/dl who have symptoms referable to their 
anaemia, particularly angina, should also be offered EPO therapy.
Whether pre-dialysis patients should routinely be treated is still unclear. There 
is a theoretical risk that raising the haematocrit would, by increasing viscosity and 
reducing renal plasma flow, impair renal perfusion and thus lead to a more rapid decline 
in renal function [160]. However, studies to date suggest that erythropoietin therapy 
has no effect on the natural history of the uraemia [116,240,243]. In our experience, 
patients with a haemoglobin concentration of less than 8 g/dl usually have either end- 
stage renal failure or another condition contributing to their anaemia such as myeloma. 
Treatment should, therefore, normally be reserved for individuals with symptomatic 
anaemia who are unlikely to need to start long-term dialysis within the next three 
months.
Whether EPO therapy will be effective in patients with a multifactorial cause for 
their anaemia, for example uraemia and rheumatoid arthritis, is uncertain. The finding 
of an inappropriately low serum erythropoietin concentration for the degree of anaemia 
[9] could be an indication for a trial of treatment, but the response may be impaired by 
the underlying chronic disease. Further experience with the use of EPO in 
multifactorial anaemia is required before this question can be fully answered since most 
of the EPO trials to date excluded such cases.
Monitoring iron status before and during treatment with EPO
It is important to determine clearly the baseline iron status of any patient being 
considered for erythropoietin therapy for two reasons.
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Firstly, if a patient is frankly iron deficient then one can expect some 
improvement in the haemoglobin concentration with iron therapy alone, either oral 
[244] or intravenous [245]. The potential cost saving following such simple therapy 
could be substantial. As a result, EPO treatment should be withheld until it is clear that 
the patient is not iron deficient, or until a deficiency has been fully treated as judged by 
a stable haemoglobin concentration. If the serum ferritin level is less than 15 pg/l, the 
patient is iron deficient. Higher concentrations of serum ferritin may be found in iron 
deficient patients, for example in conditions causing hepatocyte dysfunction or greatly 
increased iron resorption from extravasated blood. In these circumstances, the serum 
ferritin may be raised out of proportion to the iron stores. In addition, the transferrin 
saturation may also be acutely raised. If there is doubt about the patient's true iron 
status a therapeutic trial of oral or intravenous iron should be given for a minimum of 
four weeks. If there is any response during this period then EPO therapy should be 
postponed until a new stable haemoglobin concentration is achieved. At this point the 
need for EPO should be reassessed. In all cases it is important to remember that 
infection or active inflammatory processes, including peritonitis in CAPD patients, may 
prevent a response to iron therapy.
The second reason why it is important to estimate the baseline iron status of a 
patient starting EPO therapy is to determine whether there is enough readily available 
iron to meet the anticipated demand. The advent of erythropoietin has resulted in an 
unprecedented and potent therapeutic stimulus to erythropoiesis, and it has become 
apparent that large quantities of iron are utilised during this process. Thus, patients 
who are iron replete before starting EPO can rapidly become deficient under the 
influence of this treatment [1,2,91,123,124,125]. This may occur in the presence of 
a normal serum ferritin level (suggesting adequate iron stores) and stainable iron in the 
marrow, and the problem appears to be a limitation in the rate of iron supply, i.e. the 
stores are unable to release iron fast enough to meet the demand.
Previous work has shown that a rise of 1 g/dl in the circulating haemoglobin 
concentration uses 150 mg of storage iron (equivalent to nearly 20 pg/l of serum 
ferritin) [246]. Thus, for an anticipated haemoglobin rise of 5 g/dl following EPO
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therapy, the absolute minimum requirements would be 750 mg of storage iron (100 
|xg/l serum ferritin). Patients with starting serum ferritin levels less than 100 pg/l, 
therefore, are highly likely to develop functional iron deficiency. Such individuals will 
require intensive iron supplementation, almost certainly in the form of parenteral iron. 
Recently, a nomogram was devised for estimating the projected iron deficit based on the 
initial haemoglobin and serum ferritin concentrations, and assuming a target 
haemoglobin level of 11.6 g/dl [123]. The same authors also demonstrated that oral 
iron supplementation was unlikely to be able to keep pace with the demand during the 
early phase of treatment with EPO [123].
Patients with initial serum ferritin levels greater than 100 pg/l may also 
develop functional iron deficiency [91,123] which may be detected from changes in the 
percentage transferrin saturation with iron. If this falls below 20% then it is likely 
that the available iron supply to the erythron is inadequate [1,2,123,124,125].
Bainton & Finch [247] previously demonstrated that functional iron deficiency occurred 
once the transferrin saturation was reduced to levels below 16%. Thus, if the 
transferrin saturation falls below 20% at any stage of EPO treatment, parenteral iron 
therapy is indicated. More recently, a new and more direct method of detecting 
functional iron deficiency has been reported [248]; the initial results are encouraging 
and further investigation is merited.
Figure 46 presents an algorithm for managing patients on EPO therapy, with 
particular emphasis on the monitoring of iron status and the need for iron 
supplementation.
What starting dose of EPO and which route of administration?
Most experience with EPO so far is with intravenous therapy in haemodialysis 
patients, and one of the earliest studies showed that there was a dose-dependent rate of 
response to erythropoietin [91]. However, it has become increasingly accepted that the 
risk of side-effects such as severe hypertension and thrombotic complications may be 
lessened with a haemoglobin rise not exceeding 1 g/dl/month. Most workers using 
intravenous EPO now prescribe an initial dose in the range of 100-200 U/kg/week for
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haemodialysis patients, divided into 2 or 3 doses. A similar intravenous dosage regimen 
has been used with good effect in patients not yet on dialysis [116,240,243].
The intravenous route is clearly impractical for chronic use in CAPD patients 
who have no ready vascular access. Obvious alternatives to be considered included the 
intraperitoneal and subcutaneous routes. In a single-dose pharmacokinetic study in 
CAPD patients, the bioavailability of subcutaneously-administered erythropoietin was 
found to be seven times greater than that of intraperitoneal administration, but was still 
only 22% (see Chapter 1) [99]. These results were subsequently confirmed by 
Boelaert et al. [104]. Nevertheless, Frenken et al. [103] used the intraperitoneal route 
for treating 5 CAPD patients, and obtained an effective clinical response with a dose of 
300 U/kg/week (3 separate administrations). Similar haemoglobin responses, 
however, were reported in 9 CAPD patients and 12 haemodialysis patients treated with 
only 120 U/kg/week (2 separate administrations) given subcutaneously [127,129]. 
This dose achieved a similar correction of anaemia to that obtained with 240 U/kg/week 
(2 administrations) given intravenously to a group of 10 haemodialysis patients [129]. 
The overall rate of response, however, was slightly slower.
Bommer et al. [114] showed that a 50% reduction in dose can be achieved when 
switching from intravenous to subcutaneous administration with no loss of effect.
Stevens et al. [117] treated 12 CAPD patients with subcutaneous EPO and obtained a 
brisk response to 300 or 450 U/kg/week (3 administrations). The dose was then 
reduced to 37.5-150 U/kg (median 75 U/kg) weekly to maintain a haemoglobin 
concentration between 11.0 and 11.5 g/dl. A similarly rapid response was obtained in 
another study of five transfusion-dependent children on CCPD in whom the haematocrit 
increased from 22% to 33% after only 3 weeks' treatment with EPO given SC at an 
initial dose of 450 U/kg/week (3 administrations) [119]. A much lower SC dose of 100 
U/kg/week (2 administrations) was used by Steinhauer et al. [118] to treat eight adult 
CAPD patients. In pre-dialysis patients, similar responses were achieved with 450 
U/kg/week (3 administrations) intravenously and 300 U/kg/week (3 administrations) 
subcutaneously [116]. The lowest total weekly dose of EPO reported to be effective to 
date (98 U/kg/week) was also given via the subcutaneous route in a study by
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Granolleras et al. [115]. These workers obtained an adequate haemopoietic response in 
haemodialysis patients with daily SC injections of only 14 U/kg.
Thus, the subcutaneous route appears to be gaining in popularity not only in 
CAPD patients [117,127] but also in haemodialysis subjects [115,129], and the 
evidence to date suggests that lower doses of EPO may be used when given by this route. 
Further dose-finding studies are required, but on the evidence available a starting 
subcutaneous dose in the range of 75-150 U/kg/week in 2 or 3 divided doses seems 
appropriate. If the patients can be taught to give their own injections, then the daily 
dosage regimen [115] may be worth considering.
What target haemoglobin concentration should be aimed for?
There is little doubt that it is possible to correct fully the anaemia of chronic 
renal failure with EPO. In balancing the benefits versus the risks, however, the 
common practice is to aim for partial correction. A linear increase in the haemoglobin 
concentration or haematocrit leads to an exponential rise in whole blood viscosity (see 
Chapter 4) [173,185,187] which, in turn, is thought to contribute to many of the 
side-effects of EPO therapy such as hypertension, increased peripheral resistance, and 
thrombotic complications. In addition, it appears that this partial correction of the 
anaemia causes near-maximal improvement in well-being, exercise capacity 
[154,158], and symptoms of anaemia. A further increase in the haemoglobin 
concentration does not seem to confer any additional symptomatic benefit [249], and 
would therefore be less cost-effective.
The optimal target haemoglobin concentration seems to be in the range of 10-12 
g/dl. It is at this level that the risk:benefit ratio appears to be minimised though some 
flexibility is necessary in treating individual patients. Since the main aim of EPO 
therapy is to reverse the symptoms of anaemia, differing thresholds at which this occurs 
may influence the appropriate final haemoglobin concentration.
With regard to the rate of rise of the haemoglobin response, for most patients an 
increase of 1 g/dl/month appears to be a reasonable compromise. Exceeding this limit
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may predispose the patient to an increased risk of side-effects, and there is rarely any 
indication for more rapid correction of anaemia.
What if there is an impaired haemopoietic response to EPO ?
The large multicentre trials of EPO in the United States of America and Europe 
indicate that 95-98% of patients treated will respond [159]. Nevertheless, there is 
undoubtedly a small proportion of patients who have either no response or a grossly 
inadequate one. Even though some of these patients will respond to a much higher dose of 
EPO, a precipitating cause should first be sought (Table 12). The most common problem 
is undoubtedly an inadequate supply of available iron, as discussed earlier. Other forms 
of haematinic deficiency, such as vitamin B12 or folate, are less common and should 
have been excluded before starting treatment. Aluminium toxicity is another cause of 
erythropoietin resistance, but results from a recent European multicentre trial showed 
that this has to be severe before haemopoiesis is inhibited [250]. High parathyroid 
hormone levels inhibit erythropoiesis in vitro [24], but the clinical relevance of these 
findings remains controversial [250,251,252]. Infection, either acute or chronic, as 
well as occult malignancy are potent suppressors of erythropoietic activity, and several 
cases have been reported in which this has occurred (see Chapter 2; Fig. 11) [90].
All the above causes of erythropoietin resistance represent examples of an 
inadequate haemopoietic response. The other possibility is that erythropoietin is 
effective in initiating enhanced erythropoietic activity, but that there is also increased 
red cell loss, either through haemolysis or blood loss. A clue to this may be an enhanced 
reticulocyte response to EPO which is not reflected in any change in the haemoglobin 
concentration.
Thus, patients showing a poor response to EPO, or loss of a previous response, 
require investigation for an underlying cause. Haematinic deficiency, aluminium 
toxicity, haemolysis, and blood loss can be relatively easily excluded, although occult 
infection or malignancy may prove more difficult. It may be possible to override some 
of these causes of erythropoietin resistance with a higher dose of EPO, but the 
importance of excluding them should not be disregarded.
Potential complications
A number of possible complications of EPO therapy have been described, 
including hypertension [90,91,92,159,173], thrombosis of the arteriovenous fistula 
[90,92,93,174,175], flu-like symptoms [90,92,174], and increased pre-dialysis 
plasma potassium concentrations [91,92]. Hypertension occurs the most frequently, 
and is potentially the most serious consequence of this treatment, occasionally resulting 
in seizures or encephalopathy. It has been suggested that this is more common in 
patients with a previous history of hypertension [92], but a large multicentre trial 
showed no greater risk of a rise in blood pressure between those previously 
hypertensive and those who were originally normotensive [253]. It is therefore 
essential that arterial pressure is well-controlled before commencing EPO therapy and 
that the patient is monitored frequently. Although any increase in blood pressure can 
usually be controlled by hypotensive agents [253], a rise in blood pressure may be an 
indication for reducing the dose of EPO with a consequent reduction in haemoglobin 
concentration. In other patients blood pressure control may be facilitated by aiming for 
a lower target haemoglobin concentration.
Thrombosis of the arteriovenous fistula was of some concern in the early studies 
of EPO treatment [90,92,93], and a recent placebo-controlled multicentre trial 
suggested that there is a significantly increased risk of this complication developing in 
patients receiving the hormone [175]. Whether this is exacerbated by the increase in 
blood viscosity (see Chapter 4) [173,185,187], changes in platelet function 
[206,207,208,209], or a reduction in protein C and protein S levels (see Chapter 5) 
[210] requires further elucidation.
Flu-like symptoms have been recorded in a few patients early in the course of 
EPO therapy [90,92,174], but these are of no consequence and disappear even if 
treatment is continued. Genuine intolerance to erythropoietin sufficient to warrant 
stopping the hormone is rare. To date, there have been no reports of antibody formation 
[254] .
Some haemodialysis patients are noted to have higher pre-dialysis potassium and 
phosphate levels with a rising haematocrit [91,92]. In a few individuals this may be
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due to increased dietary intake resulting from the general improvement in well-being. 
However, it is possible that dialyser potassium clearance is lower with higher 
haemoglobin concentrations [255]. Thus, dietary guidelines should be reinforced for all 
patients starting EPO treatment.
Table 12 Potential causes of resistance to erythropoietin therapy
1 . DECREASED RED CELL PRODUCTION
( i ) Iron deficiency
( i i )  B 12/folate deficiency
( i i i ) Aluminium toxicity
( i v ) Hyperparathyroidism/marrow fibrosis
( v )  Infection - acute
chronic
occult
( v i )  Malignancy - ? occult
( v i i )  Poor absorption of erythropoietin (if given subcutaneously)
( v i i i )  Marrow dysfunction
( i x )  Red cell enzyme abnormalities, e.g. pyruvate kinase deficiency
2. DECREASED RED CELL SURVIVAL
( i ) Blood loss - dialysis
other ? gastrointestinal tract, ? occult
( i i ) Haemolysis
Treat as appropriate
Treat with 
erythropoietin
Starting ferritin 
100-1000 pg/i
Starting ferritin 
>1000 pg/l
Starting ferritin 
15-100 pg/l
No strong indication 
for erythropoietin
Hb >8 g/dl; 
asymptomatic
Hb <8g/dl; or Hb >8g/d1 plus 
symptoms of anaemia
Less likely to develop 
functional iron deficiency 
with erythropoietin
Unlikely to develop 
functional iron deficiency 
with erythropoietin
Prophylactic oral iron 
supplementation: ferrous 
sulphate 200-600 mg/day
High probability of developing 
functional iron deficiency with 
erythropoietin
Patient with end-stage renal failure and anaemia
Give 2 ml iron dextran intravenously 
every week for first 6-8 weeks of 
erythropoietin treatment
Give erythropoietin 100-200 U/kg/week 
intravenously or 75-150 U/kg/week 
subcutaneously in divided doses
Consider and exclude:
•  Deficiency of iron, vitamin B-j 2 , or folate: ferritin, B'1'2 . folate concentrations
•  Blood loss ? occult: faecal occult blood tests, 59Fe blood loss studies
•  Haemolysis: blood film, reticulocytes, haptoglobins, Coombs test
•  Infection or inflammation ? occult: plasma viscosity, C reactive protein, etc, as appropriate
•  Aluminium toxicity: aluminium concentrations, desferrioxamine test
Monitor:
•  Hb concentrations and reticulocytes every week
•  Ferritin and transferrin saturation every 2 weeks
Consider occult infection, 
malignancy, blood loss, etc
No
Treat underlying cause Increase dose of erythropoietin
If poor Hb response If transferrin
(<1g/dl/month) saturation <20%
Probable functional 
iron deficiency
Give intravenous iron dextran 
2 ml/week for 4-6 weeks
46 Clinical algorithm for treating renal anaemia with recombinant human 
erythropoietin therapy.
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1 1 . CONCLUSIONS
The last decade has been an exciting one not only for investigators working in the 
field of erythropoietin, but also for the patients who have benefitted from this 
revolutionary new treatment. The pace of progress has been rapid, with the journey 
from isolation of the human EPO gene, to its cloning, to animal testing, and to clinical use 
proceeding with remarkable speed and a notable lack of serious problems. The gene for 
human EPO was found in 1983 [53], the recombinant hormone was tested in mice and 
dogs by the Amgen Corporation in 1984-1985 [54], and the first clinical trials in 
human haemodialysis patients began in December 1985 [91].
Recombinant human erythropoietin (or epoetin, as it has subsequently been 
named) became licensed for the treatment of renal anaemia by the Food and Drug 
Administration (FDA) in the USA on 1st June 1989; several European countries 
followed suit, and the drug was finally licensed for use in the UK in May 1990. During 
this period, many thousands of renal patients worldwide have been treated, with striking 
improvements in their quality of life and sense of well-being. The secondary 
consequences of a rise in haemoglobin concentration have gradually emerged, and much of 
the work reported in this thesis has advanced this knowledge. In this respect, the 
findings from the study of long-term cardiorespiratory effects of EPO therapy published 
in the Lancet in March 1990 (and reported in Chapter 3 of this thesis) gave the first 
objective evidence of improved cardiac function, and the reversal of myocardial 
ischaemia and regression of left ventricular hypertrophy following treatment with EPO 
suggests that we might yet anticipate a long-term improvement in morbidity and 
mortality in treated dialysis patients.
The pharmacokinetic results detailed in Chapter 1 suggested that the 
subcutaneous route might be the most practical one for administering EPO to both 
haemodialysis and CAPD patients. Since then, numerous studies (including those 
documented in Chapter 2) have reported on the efficacy of SC-administered EPO therapy 
[114,115,116,117,118,119,127,128,129], and there is accumulating evidence that 
lower doses may be used when given by this route than when given IV. In addition, the
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pharmacokinetic study cast serious doubt on the practicability of using IP-administered 
EPO in CAPD patients; apart from a preliminary report in 5 patients treated with IP 
EPO [103], this route of administration has since become obsolete.
Concern still exists over the possible development of hypertensive and 
thrombotic complications in dialysis patients treated with EPO. While the pathogenesis 
of these side-effects remains unclear, the detailed studies on biood viscosity and 
coagulation parameters reported in Chapters 4 and 5 yielded useful information 
regarding possible contributory factors. In this respect, it has been interesting to learn 
that recent studies of rheumatoid arthritis patients treated with EPO [256,257,258] 
have not witnessed the hypertensive problems with EPO that have been evident in the 
studies on renal patients.
The difficulties with 125l-labelled EPO reported in Chapter 6 were not predicted 
and, to some extent, hampered progress in this field. There is still remarkable 
ignorance surrounding the organ distribution and metabolic fate of either endogenous or 
recombinant EPO, and further studies are required.
What then of the future? Attentions have more recently turned to focus on other 
applications of EPO therapy. Preliminary reports suggest that it may have a role in the 
management of anaemic conditions other than that associated with end-stage renal 
disease. These include the anaemias associated with AIDS therapy [259,260], malignant 
disease [261] and cancer chemotherapy [262], prematurity [263,264,265], 
rheumatoid arthritis [256,257,258], sickle-cell anaemia [266,267], and 
myelodysplastic syndrome [268,269], in addition to increasing supplies of autologous 
blood for peri-operative use during surgery [270,271]. Of greater concern is the 
alleged increasing use, or rather abuse, of EPO in sports medicine. By boosting "super­
haemoglobin" levels in athletes, EPO has the same effect as high-altitude training in 
increasing the exercise capacity and stamina of marathon runners and long-distance 
cyclists. Detection of this abuse is extremely difficult owing to the identical structural 
and immunological properties of the recombinant product compared with the native 
endogenous hormone.
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With the exception of this potential for abuse in sports medicine, however, the 
future for EPO looks bright. It has already transformed the lives of several thousands of 
individuals, and promises to yield further exciting prospects for many years to come.
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